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ABSTRACT 
 
PURSUING THE ROLES OF NON-INVASIVE BIOMARKERS IN CHRONIC RENAL 
ALLOGRAFT DYSFUNCTION 
By Mba Uzoma U. Mba, M.S. 
A dissertation submitted In partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2014 
Directors:  
 
Vladimir I. Vladimirov, M.D., Ph.D. 
Assistant Professor, Department of Psychiatry, Virginia Institute for Psychiatric and 
Behavioral Genetics 
 
Catherine I. Dumur, Ph.D. 
Associate Director of Molecular Diagnostics Division & Associate Professor of 
Pathology 
 
 
 
Kidney failure affects over 600,000 people in the United States with over 100,000 new 
cases of kidney failure diagnosed every year. Chronic allograft dysfunction (CAD), a 
disease state highlighted by a decreased eGFR and a histo-pathological diagnosis 
interstitial fibrosis and renal tubular atrophy, has emerged as one of the leading causes 
of kidney transplantation. Gene expression analysis can identify reproducible patterns of 
disease in ribonucleic acid (RNA) expression and may provide insights into the quality 
of kidney donations heretofore overlooked by current clinical analytical methods. 
Additionally, genetic expression profiles can be obtained from patient blood or urine 
samples, diminishing the necessity of costly and invasive tissue biopsies. Micro-RNA 
(miR) profiles have been obtained from non-invasive sources and shown to act as 
biomarkers of CAD. Specifically, miR-142-3p, miR-204, and miR-211 are shown to be 
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differentially expressed in both tissue and urine samples of patients with CAD. The role 
of these CAD-specific miRs in disease development is not well understood, but given 
the nature of miR function, they may play a significant role in CAD development.  
An independent validation of CAD-specific miR expression was done in 155 deceased 
donor transplant recipients using RT-qPCR. This new patient cohort delineated the 
importance of both decreased clinical renal function as measure by GFR, and 
diagnosed histopathology in identifying CAD.  Previous work delineating a messenger 
RNA signature of CAD was used to produce a list of potential targets for CAD-specific 
miRs via in silico analysis.  Briefly, targets for each miR were consolidated from 11 miR-
targeting networks: PITA, miRanda, TargetScan 5.1, DNA-microT, NBmiRTar, 
MicroInspector, PicTar, MirTarget2, RNA22, miTarget, and RNA hybrid (all can be found 
at: http://c1.accurascience.com/miRecords/prediction_query.php). Targets that 
appeared in at least 3 of databases were considered for further study. Experimental 
targets were then chosen according to negative Pearson correlations of miR/mRNA 
pairings and potential roles in apoptosis or fibrogenesis.  Urine samples showed 
differential expression of transmembrane protein 14A (miR-142-3p target), CD44 
molecule (miR-204), basic helix-loop-helix family member e41 (miR-204), and dual 
specificity kinase 6 (miR-211) between patients with CAD and those with normal 
allografts.  Human embryonic kidney (HEK) cell lines were used to validate these 
targets via transfection of the CAD-specific miRs and observing the modulation of their 
selected gene targets. Overexpression the CAD-specific miRs in HEK cells modulated 
their respective target gene expression. The relationship between CAD-miRs and their 
targets was validated using luciferase expression. This research verifies the differential 
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expression of these CAD-specific miRs from non-invasive sources, and validates gene 
targets for these miRs that modulate significant biological pathways in the development 
of CAD. 
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INTRODUCTION 
 
 
Normal Renal Function, Glomerular Filtration Rate & Renal Failure 
 
 
End stage renal disease (ESRD) is defined as renal failure that requires hemodialysis 
and kidney transplant (1-7).  Normally, the kidneys receive about 25% of cardiac output 
and filter the blood of waste, maintain electrolyte balance in the body, and produce urine 
as a means of controlling fluid balance (8). The nephron, an interface of renal tubules 
and blood vessels, is the functional unit of the kidney. Blood flows into the kidney via the 
renal artery and passes through the arterial tree to the afferent arteriole. From the 
afferent arteriole, blood enters the glomerulus, the functional beginning of the nephron, 
which is made up of highly fenestrated glomerular capillaries and the Bowman’s space, 
the tubular tissue comprised of podocytes that surrounds and interfaces with the 
capillaries and vaguely resembles a wrench in cross-sectional views (Fig 1) (8). The 
glomerular capillaries fuse on the other end of the glomerulus to form the efferent 
arteriole which continues to travel with and around the nephron as the peritubular 
capillary in order to aid fluid and electrolyte balance (8).  
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Figure 1. A schematic representation of the nephron and its functions; from: 
http://www.wickersham.us/anne/peelab.htm 
Filtration from the glomerular capillaries into the Bowman’s space is governed chiefly by 
Starling forces that result in a net push of fluid and nutrients from the capillaries into the 
Bowman’s space (8).  In healthy functioning kidneys, water, electrolytes, 
oligosaccharides, oligopeptides, and soluble metabolites are filtered into the nephron’s 
tubules and over 99% of the filtrate is reabsorbed in the nephron (8). Filtrate flows from 
the Bowman’s space into the proximal (convoluted) tubule where the majority of water, 
sodium, and simple sugars and oligopeptides/amino acids are reabsorbed (8). The 
filtrate then enters the Loop of Henle (LoH) that descends into, and ascends from, the 
renal medulla. In the descending portion of the LoH, water is reabsorbed into the 
hyperosmotic renal medulla (8). The ascending LoH is impermeable to water and is a 
major site of electrolyte regulation via the 3-ion (Na+/K+/Cl-) co-transporter (8). The distal 
tubule continues from the ascending LoH and controls Ca2+, Na+, and water 
reabsorption as well as acid secretion via pharmacologic or hormonal control of 
ion/water channel proteins (8). Water reabsorption can continue beyond the distal 
tubule in the collecting ducts as needed (8). Collecting ducts are the functional end of 
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the nephron as they coalesce into the renal calices that form the renal pelvis and ureter 
that transmit the remaining filtrate, now urine from the kidney into the bladder for 
excretion.  
Waste products that do not enter the renal tubules via the glomerulus can alternatively 
be secreted into the tubules from the peritubular capillaries for excretion in the urine (8). 
Clinical monitoring of renal function is based on the urine and/or serum levels of 
chemical markers.  Renal markers are generally freely filtered but not reabsorbed by, or 
secreted into the nephron (8). They can be exogenous for optimal study, as done with 
the plant carbohydrate inulin; or endogenous for easy measurement, as done with 
creatinine (8).  Measuring the serum levels of creatinine is the most expedient, and 
thus, widely used method of monitoring renal function. Direct measurement of creatinine 
can be used singularly to assess renal health, but the glomerular filtration rate (GFR), a 
creatinine-based estimation of renal function calculated below (Eq. 1), is the current 
clinical standard for monitoring renal function (9-12).  
Equation 1. MDRD Estimated GFR = 175*(sCr-1.154) x (Age-0.203) x [1.212, if Black] x [0.742, if Female] 
The equation uses a correction coefficient (175) that accounts for the units of serum 
creatinine (sCr), mg/dL, and the manner in which sCr is measured (11;12). The 
exponential coefficient for serum creatinine, -1.154, indicates that a 1% increase in sCr 
results in a 1.154% drop in eGFR (11;12). At any sCr level, increasing age  and being 
female are linked to lower GFR, while being Black is associated with higher GFR 
(11;12). The equation ignores the individual’s height and weight by normalizing the 
results to an average body surface area of 1.73m2, making  over estimations in 
underweight persons and underestimations for people who are overweight or have large 
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muscle mass (12).  In the clinical setting, an eGFR >60 ml/min/1.73m2 is considered 
normal post-transplant function (9-12), and renal failure is marked by a sudden (acute) 
or progressive (chronic) decrease in GFR. Functionally, the drop in GFR is a reflection 
of the nephron’s inability to efficiently filter the blood due to a variety of reasons, 
otherwise known as renal failure. Histologically, renal failure is typified by some 
combination of the thickening of glomerular basement membranes, obliteration of renal 
tubules, a decrease/loss of blood flow through the peritubular capillaries, and in some 
cases, infiltration of immune cells & lymphatic fluids (Fig.2). These tissue changes 
produce the picture of the physical alterations leading to the characteristic loss of 
filtration associated with renal failure. Molecularly, renal failure is combination of 
fibrogenesis, inflammation and apoptosis working alone or in concert to destroy the 
normal functioning kidney. 
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A.  
B.  
Figure 2. Histological sections of (A) normal kidney biopsy tissue, and (B) chronic renal failure 
biopsy tissue 
  
 
 
Transplantation, Donor Quality, DGF & CAD 
 
 
By the end of 2011, 616,000 U.S. residents were being treated for ESRD with over 
115,000 new cases in that same year (13). There are various etiologies of renal failure 
including, but not limited to: diabetes mellitus, hypertension, trauma, autoimmune 
diseases, drug toxicity, genetic disorders, and graft failure (1;6). As of 2012, the most 
prevalent causes of primary renal failure among the over 90,000 adults awaiting 
transplant are diabetes mellitus (34.2%), hypertension (25.0%), glomerulonephritis 
(14.1%), polycystic kidney diease (8.2%), and other/idiopathic causes (18.5%) (6). 
Hemodialysis is the most common treatment measure for ESRD as over two-thirds of 
ESRD patients (approx. 430,000) are actively undergoing this treatment (13). In 2009, 
there were over 90,000 deaths among persons being treated for ESRD (14).  The 
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ESRD mortality rate, coupled with patient costs cresting $42 billion, highlight the need 
for more effective treatments beyond hemodialysis which accounts for the bulk of 
treatment costs (14). Renal transplantation is a cheaper and more permanent treatment 
for ESRD (14).  Presently, there are approximately 18,000 renal transplantations per 
year in the United States (14), but the pace of renal transplantation only covers 20% of 
the 90,000 persons who are currently on the national waiting list for a new kidney (1).  
Rising ESRD patient populations and a limited supply of useable organs have made 
optimizing the process and results of renal transplantation of the utmost importance in 
treating the disease.  Ideally, all ESRD patients would receive living related donor 
kidneys (LRDKs), as those organs are associated with the best long term outcomes 
(6;15). LRDKs are not exposed to ischemia and are far less likely to exhibit any 
immune-reactivity in the recipient compared to living unrelated donor (LURD) kidneys or 
deceased donor kidneys (DDKs). Despite the higher quality of living donor transplants, 
the dearth of organs is such that approximately 2/3 of the nearly 18,000 renal 
transplants performed in 2011 were from deceased donors (6).  Improvements in organ 
handling and perfusion pump use have allowed for both better assessment of deceased 
donor organs (16-20) and the use of donations previously believed to be too aged or 
damaged for use as a graft (4;16-21).  Efforts to increase the number of donations have 
led to use of organs donated after cardiac death (DCD) and a class of donations from 
patient populations that were previously ignored as donors (21;22). These expanded 
criteria donors (ECD) have specific criteria seen in table 1.   
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Table 1. Expanded Criteria Donor Characteristics (22;23) 
Donor Age Comorbidities (2 or more) 
>60 None 
50-59 Elevated Creatinine (>1.5 mg/dL) 
Hypertension history 
Death by cerebrovascular accident 
(Stroke) 
Use of 2+ vasopressors 
 
Lack of suitable organs has kept the prevalence of transplanted kidneys low 
(approximately 172,000 as of 2009) (14), but improvements in type matching, immuno-
suppression, and effective prophylaxis have significantly reduced hyperacute and acute 
graft rejection as significant causes of graft failure (3;5;23).  Graft failure, measured 
independently of the previously mentioned causes of ESRD, accounts for a full 14.5% of 
patients awaiting a transplant (6).  From 2002-2012, the prevalence of graft failure 
dropped as a percentage of adults awaiting transplant, from 17.9% to the 
aforementioned 14.5% (6); however, the number of patients increased grossly, from 
approximately 9,000 to over 13,000 adults (6), keeping graft failure among the top 5 
causes of renal failure and highlighting the necessity of continued improvement of post-
transplant monitoring and management.  
The decrease in acute rejection events and expansion of the donation pool has 
changed the clinical picture of acute and chronic adverse events surrounding renal 
transplantation. Acutely, delayed graft function (DGF) has supplanted hyperacute and 
acute rejection as the chief post-operative adverse event during transplant.  Delayed 
graft function (DGF) is a negative short-term outcome of renal transplantation. Delayed 
graft function is a purely clinical diagnosis defined by consensus as requiring more than 
1 hemodialysis treatment in the first week post-transplant (4;7;18-20;22;24-27), typically 
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during the post-operative hospital stay.  More quantitative metrics of DGF are defined 
by the severity of oliguria (low urine output) or changes in levels of serum creatinine. 
These changes are measured in many ways including direct measurements of serum 
creatinine, ratios of pre- and post-transplant serum creatinine levels, such as creatinine 
reduction ratio on day 2 (CCR2%), or increases in GFR (4;22;26;28). The mechanism of 
DGF development is poorly understood, but there are several hypotheses on DGF 
development including DGF as a consequence of: ischemia reperfusion injury (21;24), 
inflammation and apoptosis (21;29), hypoxia-induced fibrogenesis (7), and poor donor 
quality (22;24-27;29). Despite its loose definition and the varied ideas of its origin, DGF 
is an important clinical outcome because it is independently related to the development 
of chronic rejection also known as chronic allograft dysfunction (CAD) (27;28).  Chronic 
allograft dysfunction (CAD), a state of chronic rejection typified by the histological 
diagnosis of interstitial fibrosis and tubular atrophy (IFTA), is among the leading causes 
of graft failure (3;5;23). The combination of chronic inflammation, increased 
fibrogenesis, and decreased initial nephron mass in patients with DGF create a milieu 
for histological IFTA diagnosis during the first year post-transplant, making DGF an 
independent risk factor of CAD (22;23;26;27). Additionally, the use of DCD and ECD 
organs is associated with greater rates of DGF and development of CAD.  With limited 
organs available for transplant and the lower costs of post transplant management 
compared to hemodialysis (14), novel methods for addressing the quality of kidney 
donations and post-transplant management are essential to extending the viability of 
renal transplants and improving the quality of life of renal transplant recipients. 
9 
 
Clinicians’ steadily improving ability to select and maintain renal grafts have lowered the 
risk of hyperacute and acute graft failure (4;5;30). Hyperacute graft failure occurs within 
hours of transplant. It is mediated by the recipient’s preformed antibodies attacking the 
graft’s endothelial antigens resulting in thrombotic occlusions and ischemic necrosis of 
the graft (5;31-33). Acute graft failure, also known as acute cellular rejection (ACR), 
develops in the first week post-transplant as a result of T cells and macrophages 
infiltrating the kidney parenchyma and causing necrosis (5;31-33).  Likewise, a lack or 
extended interruption of immunosuppressive treatment at any point post-transplant can 
cause ACR in graft recipients.  Immunosuppression, organ handling and short-term 
management improvements have made the progressive loss of function known as CAD 
the leading cause of graft failure with approximately 5,000 renal grafts failing every year 
(4;5;7;21;23;30;34-39). Interstitial fibrosis and tubular atrophy (IFTA) typifies the 
progressive loss of function that leads to CAD (5;30;38;40). The development of IFTA is 
poorly understood; it has been linked to poor donor quality, recipient disease, 
immunosuppressant toxicity, and most recently to certain gene products 
(5;30;38;40;41).  IFTA is primarily a histo-pathological diagnosis based on the 
evaluation of serial graft biopsies and it is most notably marked by a steady loss of 
nephron mass beyond 6 months post-transplant leading to graft loss (5;30-33;38;40).  
The onset of IFTA makes it a useful clinical identifier of chronic rejection (5;31-
33;42;43); however, because it develops slowly, IFTA cannot be used as a predictive 
tool for diagnosing CAD (3;5;31-33;42;43). Instead, IFTA exists clinically as a negative 
long term outcome of renal transplantation. 
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IFTA is a process that begins with tubulointerstitial damage that progresses into fibrotic 
scarring of renal vasculature and resulting in renal tissue dominated by fibrotic lesions 
that obliterate nephron tubules and microvasculature (2;3;37;44;45).  Initial post-
transplant renal damage appears to be secondary to ischemia reperfusion injury, drug 
nephrotoxicity, acute tubular necrosis and subclinical rejection (2;3;37;44;45). These 
factors work in conjunction with any present donor abnormalities and recipient co-
morbidities to potentially damage the kidney (2;3).  The kidney undergoes a process 
similar to epithelial-to-mesenchymal transition (EMT) during which tubular epithelial 
cells become myofibroblasts through a loss of cell-cell adhesion and E-cadherin 
expression coupled with tubular basement membrane disruption and increased 
production of fibrogenic proteins including collagen types I, III and V as well as 
fibronectin (2;3;40;46-50). As this fibrotic process occurs, renal function remains 
clinically viable until fibrotic lesions dominate the organ resulting in glomerulosclerosis 
from lack of circulation to glomeruli and thickening of basement membranes (2;3;40;45-
51).  Areas of the kidney affected by fibrosis also are surrounded by inflammatory 
infiltrate and invading immune cells (lymphocytes and macrophages/monocytes) that 
contribute to both the overall histo-pathological picture of IFTA and the chronic 
inflammatory state that provides the milieu for fibrosis to occur (2;3;45;51). Finding 
methods to target and mitigate the molecular processes important to IFTA development 
can provide a new means of monitoring grafts for signs of IFTA and even developing 
treatments for the condition. 
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Post Transplant Monitoring & Gene Expression Profiles 
 
 
Post-transplant monitoring of renal graft function remains a major challenge in 
optimizing renal graft management. Current clinical metrics for monitoring graft function 
range in effectiveness and invasiveness, but are limited to 3 major categories: plasma 
levels of drugs & waste products, urine electrolyte & protein levels, and the tissue 
biopsy (2;38;39;42;52;53). Tracking immunosuppressant plasma levels allow physicians 
to modify treatments when coupled with information about patient side effects and other 
metrics of renal function (54;55). Clinicians use plasma levels of the renal waste 
products creatinine and urea nitrogen (BUN, blood urea nitrogen) to monitor the filtration 
and secretion capacity of the kidney (38;52-58). The main advantage of measuring 
plasma levels of drugs and waste products is the ease of drawing and processing blood 
(53-55;57;58).  The chief disadvantage of measuring these plasma levels is their 
inability to properly reflect subacute changes in function (53-55;57;58). The plasticity of 
the kidney will mitigate acute increases in the levels of waste products in the blood (53-
55;57;58). This plasticity masks subclinical and chronic rejection, where there may be 
histological evidence of rejection in the absence of functional indices (53-55;57;58). 
Clinicians are left to rely on rapid increases in creatinine and BUN, indicative of 
significant renal damage, to diagnose graft dysfunction (53). Furthermore, while acute 
changes in creatinine levels suggest rejection or organ failure, any creatinine-based 
diagnoses of renal pathology require a tissue biopsy for confirmation (31;53;59-61).  
The inability to identify subclinical rejection via normal clinical surveillance makes 
managing renal allograft function more difficult than other organs with more direct links 
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between plasma biomarker expression and histological function (31;53;59-61).  
Similarly, clinical urine evaluation exhibits the same advantages as plasma analysis in 
that both methods are minimally invasive (42;53;59;61). Urine electrolytes and protein 
measurements are effective reporters of the metabolic state of the kidney; however, the 
accuracy of measurements is limited to the 24hrs surrounding the time the sample was 
taken and levels measured can vary with several factors including renal disease 
etiology and recipient dietary management (42;53;59;61). 
Histo-pathological analysis of the renal tissue biopsy is presently the gold standard for 
monitoring graft function (5;38-40;42;43;52;53;59;61). The great advantage of the tissue 
biopsy is its ability to diagnose inflammation, infection, fibrosis, glomerulosclerosis, and 
tubular atrophy before the standard clinical renal function markers at any point post-
transplant (5;32;38;42;62). The disadvantages of the tissue biopsy are the invasiveness 
of the procedure, the subjectivity of the analysis (5;42;52;61), and the current clinical 
approach for using the procedure.  Needle-core biopsies are procedures requiring 
ultrasound guidance and local anesthesia to be most successful (5;42;52;61). The 
prospect of needle use and the necessary hospital stay following the procedure lowers 
patient compliance, and subsequently the number of patients who receive the 
procedure. Single sample variability between pathologists in analyzing renal tissue 
ranges between 25-50% (5;42;61).  Additionally, in most clinical settings, tissue biopsies 
are done to confirm signs of renal failure from serum-based clinical indicators of renal 
dysfunction (GFR, creatinine and/or blood urea nitrogen, BUN) further lowering the 
biopsy’s utility as prospective marker of transplant function (42;53;61). Histologically, 
IFTA is not ascribed to any specific etiology, and is noted as Banff category 5 with 
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grades ranging from mild (grade 1) to severe (grade 3) (31-33;63). Grade 1 IFTA is 
defined as interstitial fibrosis and tubular atrophy in <25% of the renal cortical area 
sampled (31-33;63). Grade 2 is IFTA between 25 & 50% of the sampled renal cortex, 
and grade 3 is IFTA greater than 50% of the sampled renal cortex (31-33;63). 
Additionally, there is an ungraded IFTA where each element is observed alongside 
nonspecific vascular and glomerular sclerosis (63). 
The challenges with current clinical metrics reveal the necessity for less invasive and 
more accurate methods of monitoring renal grafts. Gene expression profiling is an 
increasingly viable means for meeting the challenges of graft monitoring. Gene 
expression profiles can utilize RNA retrieved from tissue, blood or urine (2-
5;21;30;34;36;52;55;56;64-67), making it an easily accessible and, particularly in the 
case of urine collection, non-invasive method of evaluating graft function 
(30;38;40;52;66;67). RNA expression is preferable because of the relative dynamism 
compared to DNA and the ease of isolation from many sources. More importantly, RNA 
expression changes can inform us about protein expression changes and the resultant 
function of the cell. The direct link between mRNA and protein expression is understood 
in relation to the central dogma, with studies explicitly illustrating that mRNA and protein 
levels are correlated as long as the mRNA and corresponding protein have the same 
cellular stability (68). These profiles represent a snapshot of cellular and, by extension, 
tissue function that can potentially be the earliest point that IFTA can be identified (64) 
(Fig 3). 
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Figure 3. Diagnosis and rejection timelines. Earlier diagnosis allows greater time for delivering effective 
treatments. Molecular diagnosis of rejection gives clinicians the most time to effectively treat patients. (9) 
Presently, messenger RNA (mRNA) profiles have been used to identify acute rejection 
(ACR), BK virus nephopathy, and chronic rejection with interstitial fibrosis and tubular 
atrophy (52). Patterns of mRNA expression linked to IFTA are linked to specific cellular 
processes including the immune response, inflammation, fibrogenesis, and apoptosis 
(2-5). Genes that hallmark these processes including, but not limited to interleukin-10 
(IL-10), transforming growth factor beta (TGF-β), and epidermal growth factor (EGF), 
have been shown to be differentially expressed in IFTA compared to normal allografts 
(5;69). Previous work done by Mas and colleagues (2008) has shown a specific pattern 
of mRNA expression associated with IFTA (2;3;5;38) (Fig 4). Briefly, in that study RNA 
was isolated from tissue biopsy samples from 23 kidney transplant patients, 17 with 
histo-pathologically diagnosed IFTA, and 24 normal donor kidneys and prepared for 
Affymetrix gene array analysis through a process of reverse transcription followed by in 
vitro transcription (2). The gene array was analyzed using the Affymetrix Gene Chip 
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operating software and Bioconductor packages in the R programming environment (2). 
The gene expression summaries for normal donor (n=24), normal allograft (n=6), and 
IFTA (n=17) tissues were estimated from probe-level data using the RMA (Robust 
Multiarray Average) method. Genes with significant expression changes across the 
three groups were identified using the Jonckheere-Terpstra test for trends in gene 
expression. This test identified genes that increased or decreased in expression from 
normal donor to normal allograft to IFTA. Gene ontology and interaction analyses were 
done to identify which cellular processes are most represented, and by extension 
altered, by the genes that are differentially expressed in IFTA. Reverse transcription 
quantitative polymerase chain reaction (RT-qPCR) experiments were used to validate 
the effect sizes and directionality of expression among genes of interest including: 
transforming growth factor beta (TGF-β), thrombospondin-1 (TSP-1) and the epidermal 
growth factor receptor (EGFR). More broadly, differentially expressed genes in IFTA 
cases are involved in the immune response, fibrogenesis, and apoptosis (2;3;5). 
Moreover, monitoring gene expression changes has led to the identification of epithelial-
mesenchymal transition (EMT), a process once only linked to tumor metastasis, as, 
potentially, a key process in renal fibrogenesis (70-73). Modulating mRNA function that 
leads to IFTA can be a potential mechanism to treat or prevent IFTA development post 
transplant. 
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Figure 4. Two dimensional hierarchical clustering of differentially expressed mRNA profiles of patient 
samples comparing CAD to normal allograft kidneys and normal kidney tissue. Green cells represent 
down-regulated genes and red cells represent up-regulated genes The bars below the dendrogram 
represent the different patient populations: CAD (light blue), normal renal allograft (dark blue), normal 
kidney (pink). The bar below the heatmap represents the colors associated with the degree of down-
regulation (green) and up-regulation (red). (2) 
 
MicroRNAs and Renal Dysfunction 
 
 
Messenger RNA from non-invasive sources like urine present a unique challenge for 
evaluating renal allografts for IFTA.  Large single stranded mRNA transcripts are 
unstable above room temperature, in alkaline pH, and in the presence of RNA 
nucleases (RNases). Fresh urine samples, especially those from renal transplant 
recipients, will have all 3 mRNA destabilizing factors. Consequently, the circumstances 
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of urine sample collection in a clinical setting make obtaining and storing urine samples 
in a manner that would preserve the integrity of any mRNA therein extremely difficult.  
Typically, isolating RNA from a standard urine sample collection results in nucleic acids 
that are short in length (<100nt) and are difficult to assess for gene expression due to 
problems probing for complete transcripts that span multiple exons. The challenges 
presented by assessing mRNA expression in urine samples call for alternative methods 
of using urine to molecularly evaluate renal allograft status. MicroRNAs (miRNA or 
miRs) provide a less complex and more consistent source of nucleic acids from non-
invasive sources, like urine (38;40;52).  
MicroRNA is a potential source of nucleic acid biomarkers for a variety of diseases, 
including renal disease.  These short (17-25nt) non-coding RNA were first discovered in 
1993, with the isolation and characterization of lin-4 in C. elegans (74). MicroRNA form 
heterologous pairs with mRNA to modulate gene expression by destabilizing mRNA and 
repressing  translation(40;65;75-80).  MicroRNA are differentially expressed in different 
tissues, found in a variety of body fluids including blood and urine, and their expression 
is associated with various diseases and cancers (79-81).  Their short length means 
miRs are far more likely to form stabilizing duplexes and remain present in and 
isolatable in urine where most RNA is in the oligonucleotide form (52).  The increased 
stability compared to mRNA make miRNA a consistently expressed source nucleic 
acids in the urine (52). The small size makes the miRNA sequences easier to probe and 
track expression than mRNAs, as miRs have fewer splice variants and no exons to fuse 
in order to have a complete transcript (52).  
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MicroRNAs “genes” are typically found in intronic DNA sequences. The majority of miRs 
are transcribed by RNA polymerase II (75) in response to specific cellular conditions like 
inflammation, infection, and cell cycle arrest (48;80;82;83). MicroRNA gene transcription 
produces the primary-miRNA (pri-miR) which is up to 2kb long and contains a hairpin 
loop with 5’ and 3’ extensions that are capped and polyadenylated respectively (75;83). 
These extensions are cleaved by the enzyme Drosha in process called cropping, 
leaving a hairpin loop 60-120nt long (75;83). The remaining hairpin loop, now called the 
precursor-miRNA (pre-miR), contains the mature miR sequence, but remains inactive. 
The pre-miR is then transported from the nucleus into the cytosol by Exportin-5 to finish 
maturation and activation (75;83).  In the cytosol, the loop of the hairpin is cleaved by 
the RNase Dicer followed by Argonaute (Ago) protein selecting the strand from the 
resulting duplex that will be the mature miR (75;83). In some cases, Ago will select 
either strand in the duplex resulting in the miR having a -3p or -5p suffix depending on 
its proximity to the 3’- or 5’-end of the pre-miR loop (80;84).  Because of this lack of 
selectivity, there are over 2500 identified miRs originating from just under 1900 miRNA-
gene sequences, according to the latest release of miRbase (85).  
The mature miR will remain bound to the Ago protein completing the RNA-induced 
silencing complex (RISC) which also includes Dicer and the GW182 protein, a glycine 
and tryptophan rich protein that is the main mediator of gene silencing upon activation 
(80;83). Once complete, the RISC finds complementary mRNA sequences to bind in the 
cytoplasm. The complementarity between miR-bound RISC  and its target mRNA is 
largely imperfect except for the 2nd-8th bases on the 5’ end of the mature miR sequence, 
called the seed sequence (83;84). Canonically, perfect complementarity between the 
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miR seed sequence and the target mRNA is required for miR activity (83;84). The 
majority of RISC-mRNA duplexes form either in the coding sequence of the mRNA 
transcript or its 3’-untranslated region (3’-UTR) resulting in mRNA translational 
repression or degradation (83;84). The transcript remains stable during translational 
repression, but the activity and recruitment of ribosomes is blocked (80;83).  Messenger 
RNA degradation involves deadenylating and uncapping the transcript allowing cytosolic 
exonucleases to break down the mRNA (80;83).  
The study of miRs in transplanted kidneys has been mostly limited to biomarker 
discovery. Many studies have looked at differential expression of miRs in ischemia 
reperfusion injury, acute rejection, renal fibrosis, and CAD with IFTA.  Ischemia 
reperfusion injury (IRI) is the leading cause of acute kidney injury post transplant 
(40;86). IRI stems from the loss of blood supply to the organ followed by reperfusion 
and subsequent microvascular damage, tubule & interstitial inflammation, and cell death 
(36;40;86). Functionally, miRs-126 & -296 protect against microvascular damage in rat 
models of IRI (40;87). Many other miRs are differentially expressed in several models of 
IRI. Chief amongst these is miR-21, which is shown to be up-regulated in murine kidney 
tissue and tubular epithelial cell models of IRI as well as patients with acute kidney 
injury (AKI) (40;86;88;89). Other IRI-up-regulated miRs in murine and cell models 
include miR-20a, miR-146a, miR-199a-3p, miR-214, miR-223, miR-142-5p and miR-
142-3p (40;88;89). Down-regulated miRs in these same models include miR-101a, miR-
187, miR-192, miR-193, miR-194, miR-218 and miR-805 (40;86;88;89).  Although these 
miRs are among the most differentially expressed in different models of IRI, they have 
not been shown to be the only biomarkers of IRI (86).  Additionally, there are no defined 
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roles of these miRs in the molecular responses to IRI that produce the histologically 
identified AKI. 
Acute rejection (ACR) events post transplant are the result of the recipient’s innate and 
adaptive immune responses to the donor organ. ACR is managed by pharmacological 
immunosuppression, but miRs can exert control over modulators of both innate and 
adaptive immunity including immune cell differentiation, cytokine production, antigen 
processing & presentation, and Toll-like receptor signaling (40;65). The miRNA-
biomarkers associated with ACR have come largely from studying human renal allograft 
biopsy tissue, as well as urine or blood samples from transplant recipients (40;65).  In 
ACR, miR-142-5p, miR-155, miR-223 and miR-320 all exhibit up-regulation in biopsy 
tissue compared to controls, while let-7c, miR-30a-3p, and miR-324 exhibited down-
regulation in the same biopsies (40;65). Urine cell pellets from patients with ACR 
showed an up-regulation of miR-10a and a down-regulation of miR-10b and miR-210 
(40). Peripheral blood mononuclear cells (PBMCs) taken from patients with ACR 
showed an up-regulation of miR-223 (40). These studies show how efficacious miRs 
can be diagnostically for ACR, but they shed little light on the role these miRs have on 
ACR development and progression. 
From a functional standpoint, miRs role in renal fibrosis is much better delineated than 
both IRI and ACR; largely because fibrogenesis is a molecular process that is not 
unique to organ transplantation or renal dysfunction, and is comparatively a far larger 
field of study. Canonically, both beneficial and pathological fibrosis is mediated by the 
transforming growth factor-beta-1 (TGF-β1) (40;46-50). TGF-β1 binds the TGF-β type II 
receptor which phosphorylates the TGF-β type I receptor to induce the function of Smad 
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proteins, the intracellular effectors of TGF-β1 signaling (40;46-50).  Several miRs in 
many tissues have been shown to regulate different portions of the TGF-β signaling 
system. 
 Renal fibrosis specifically is a consequence of chronic inflammation that triggers the 
activation of myofibroblasts that deposit extra cellular matrix proteins into the renal 
interstitium. These myofibroblasts are both native to the interstitium and can 
differentiate from tubular epithelium in a process called epithelial-to-mesenchymal 
transition (EMT). The hallmark of EMT is a loss of E-cadherin and other epithelial 
proteins as well as a loss of the basal-apical cellular morphology indicative of epithelial 
cells. The increased deposition of collagens and the loss of tubuloepithelial cells result 
in an obliteration of nephrons and loss of overall renal function over time.  
MicroRNAs affect fibrosis on nearly every level of the canonical fibrosis pathway as well 
as in renal fibrosis specifically. miR-192 has been shown to up-regulate the expression 
of E-cadherin and subsequent repression of the E-cadherin regulator, ZEB2 (40;48). 
Both of these factors are important in EMT, and miR-192 prevents the loss of E-
cadherin that is indicative of EMT (40;48). miR-192 is down-regulated in renal biopsies 
of persons with diabetic nephropathy which correlates with concurrent increases in 
tubulointerstitial fibrosis and loss of renal function (40;48). Other miRs that regulate 
renal fibrosis via EMT modulation are in the miR-200 family (miRs-200a, 200b, 200c, 
miR-141 & miR-429), which like miR-192 inhibit ZEB2 to decrease fibrogenesis (40;48). 
Additionally, the miR-200 family also inhibits ZEB1 resulting in increased E-cadherin 
expression (40;48). Two members of the miR-200 family, miR-200a and miR-141, 
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directly regulate the TGF-β signaling pathway through inhibiting the TGF-β2 ligand 
(40;48).   
Another regulator of the TGF-β signaling pathway is the miR-29 family (-29a, b, & c) 
which is mostly associated with inhibiting fibrosis in the heart, liver, and lungs (40;48). In 
the kidney, miR-29 inhibits collagen expression and modulates matrix protein function 
(40;48). In vitro, TGF-β1 expression will reduce miR-29 expression in tubular epithelium 
and podocytes; however, the activity of the miR-29 family is not completely uniform 
(40;48). Murine and in vitro models of diabetic nephropathy show that miR-29c may up-
regulate matrix protein expression and fibrosis (40;48). These findings make delineating 
the role of miR-29 more difficult and require observing miR-expression in different 
etiologies of renal fibrosis/failure. miR-21 has several observed roles in renal fibrosis. 
Originally observed as cardio-fibrogenic (40;41;48;89;90), miR-21 has exhibited pro-
fibrotic renal expression in both human and murine models of fibrosis (41). Within the 
canonical fibrosis signaling pathway, miR-21 targets smad7, an inhibitory regulator of 
TGF-β mediated fibrosis (40;41;48;89-91). miR-21 also has demonstrated effects on 
peroxisome proliferator-activated receptor-α (PPARα), a regulator of lipid metabolism 
that mitigates renal injury and fibrogenesis, as well as MPV171, an inhibitor of 
mitochondrial reactive oxygen species production (40;41;48;90). Having both direct and 
indirect ties to renal fibrogenesis makes miR-21 a prime molecule for further study and 
a potential treatment target for treating or preventing fibrosis. Another miR that 
regulates non-canonical fibrogenic pathways is miR-324. miR-324 is up-regulated in a 
murine model of renal fibrosis and targets prolyl endopeptidase (48;92), an enzyme that 
metabolizes angiotensin and produces the anti-fibrotic peptide, Ac-SDKP (92). The pro-
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fibrotic effects of miR-324 are mitigated by ACE inhibitors and illustrate a TGF-β and 
EMT independent mechanism of renal fibrosis.  
MicroRNAs and Chronic Allograft Dysfunction 
 
 
Unlike renal fibrosis, very little is understood about how miRs affect the development of 
CAD with IFTA. Differentially expressed miRs in transplant recipients with IFTA 
compared to those without provide insight into what miRs can be used as prospective 
diagnostic markers. MicroRNA sequence profiles comparing tissue biopsies from 
transplant recipients with IFTA to those without show an up-regulation of miR-21, miR-
142-3p &-5p, and miR-506 and a down-regulation of miR-30b and miR-30c (93).  These 
results were from a limited patient population (n=26) that included both living and 
deceased donor kidneys (93). An array-based miRNA expression profile comparing 
tissue biopsies from deceased donor transplant recipients with IFTA to those without 
IFTA showed an up-regulation of miR-142-3p & miR-32 and a down-regulation of miR-
107, miR-204, and miR-211 (38). Studies that looked at differential miRNA-expression 
in urine samples either exclusively, or in addition to tissue biopsy miRNA expression 
showed differential expression of miR-125 (52), miR-203 (52), miR-142-3p (38;52), miR-
204 (38;52), and miR-211 (38;52). These array based studies looked exclusively at 
deceased donor kidney of varying quality (DCD, ECD, & standard criteria donors, SCD) 
and validated the array results using RT-qPCR (38;52). The homogenization of donor 
type (living vs. deceased) is an important factor to consider when evaluating gene 
expression because the living donor kidneys are not exposed to the same caliber of 
stresses as deceased donor kidneys. Consequently, living donor kidneys have a much 
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lower potential for ischemia reperfusion injury, acute kidney injury, and delayed graft 
function (94-96); all of which are correlated to the development of chronic rejection.  
Recent work by Scian et. al in 2011 has shown that 3 miRs; miR-142-3p, miR-204, and 
miR-211; are differentially expressed in both tissue and urine samples from renal 
transplant patients diagnosed with CAD with IFTA and patients who would later develop 
CAD with IFTA (38;52). While these results show some promise for using miRs as part 
of a new paradigm for prospective graft management, little is understood about how 
these miRs affect renal function in a manner that would steer the kidney toward CAD 
with IFTA. The same study that identified miRs-142-3p, -204, & -211 as prospective 
CAD with IFTA biomarkers, also used in-silico statistical analysis of the mRNA 
expression signature from the same study cohort to identify potential targets for these 
miRs (38). These targets include genes that play a role in the immune, inflammatory, 
fibrotic, and apoptotic regulatory processes and could provide some insight into the 
manner in which these IFTA miRs effect the development of IFTA (38).  
MicroRNA-142-3p is on chromosome 17 and is significant in the development of acute 
cellular rejection and may inhibit the immune-suppressing functions of regulatory T 
(TReg) cells (40;65). TReg cell inhibition is linked to miR-142-3p’s down-regulation of 
adenylate cyclase 9 (AC9) (97). This action is also implicated in the oncogenesis of 
human T-cell acute lymphoblastic leukemia (98). Additionally, miR-142-3p down-
regulation is associated with, and potentially diagnostic for human acute myeloid 
leukemia .  miR-142-3p expression is up-regulated in patients with IFTA (40;52).  In an 
effort to identify potential targets for miR-142-3p and the other miRs that are 
differentially expressed in IFTA, correlation analyses were done comparing the IFTA 
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miR expression profiles to the independently generated mRNA gene expression profile 
seen previously (Fig. 4). Pearson correlation coefficients and P-values were calculated 
for each miR/mRNA pairing using differentially expressed IFTA miRs (n = 15) and 
mRNA gene probe sets (n = 2223). These calculations were followed by permutation 
analyses between the miR/mRNA pairings to determine the statistical significance of the 
pairings. Such analyses have the added benefit of developing a null distribution for the 
data in question. The mRNA IFTA signature genes that are most negatively correlated 
with miR-142-3p up-regulation play roles in microbial defense, IP3 receptor degradation, 
and apoptosis (38) (Table 2). Specifically, transmembrane protein 14A (TMEM14A, 
Table 2) is involved in apoptosis inhibition through stabilization of the mitochondrial 
membrane potential (99). Decreased TMEM14A activity as a result of increased miR-
142-3p expression could be a potential cause of Bcl-2 mediated apoptosis in renal cells, 
a process that can be reasonably linked to IFTA development.  
Table 2. miR-142-3p negatively correlated targets. Genes are according to their 
negative correlation to miR expression. The significance of the negative correlation is 
delineated by the p-value. The empirical p-value measures the statistical significance of 
the miR/mRNA pairings compared to a null distribution of randomized miR/mRNA 
pairings from the same data set (38). 
MicroRNA Probeset Gene Symbol 
Pearson 
Coefficient p-value 
Empirical 
p-value 
hsa-miR-142-3p 210397_at DEFB1 -0.977 1.15E-06 4.68E-05 
hsa-miR-142-3p 218477_at TMEM14A -0.966 5.33E-06 4.99E-04 
hsa-miR-142-3p 206716_at UMOD -0.965 6.33E-06 6.25E-04 
hsa-miR-142-3p 221542_s_at ERLIN2 -0.964 7.20E-06 7.09E-04 
hsa-miR-142-3p 204485_s_at TOM1L1 -0.962 8.69E-06 8.34E-04 
 
MicroRNA-204 is down regulated in IFTA (40;52). Found on chromosome 9, miR-204 is 
associated with maintenance of epithelial integrity when its function is coupled with miR-
211, whose expression is also down-regulated in IFTA (40;100). Both miRs-204 & 211 
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target mRNAs in the TGF-β signaling cascade relating to different diseases (100-102). 
miR-204 has also been linked to targets involved in the endoplasmic reticulum’s stress 
response such as Bcl-2-L2, an apoptosis inhibitor (103). Moreover, miR-204 stimulates 
an anti-autophagy signal in cardiomyocytes and suppresses apoptotic signaling in 
pulmonary arterial smooth muscle and HeLa cells (40).  These targets implicate miR-
204’s down-regulation of both apoptotic and fibrogenic processes. The mRNA CAD-
IFTA signature genes that are most negatively correlated with miR-204 expression play 
roles in inflammation, apoptosis and fibrogenesis (Table 3). Chief among these are the 
basic helix-loop-helix family member e41 (BHLHE41) and CD44-standard molecule 
(CD44s) (38) (Table 3). BHLHE41is a transcription factor that can act as a 
transcriptional repressor (104-106). It has several roles including the negative feedback 
of the interferon-beta (IFN-β) inflammatory response (104). Additionally, BHLHE41 is a 
demonstrated apoptosis inhibitor in cancer cell models (105;106). CD44s is a cell 
surface glycoprotein that is involved with cell adhesion and migration. It is not highly 
expressed in normal renal tissue, but its levels increase following renal injury (107-112). 
CD44s acts to up-regulate collagen degradation (107-112), and Rouschop and 
associates showed that mice lacking CD44 have increased tubular atrophy but 
decreased fibrosis following obstruction nephropathy (107). CD44s also plays a key role 
in TGF-β1 induced apoptosis and fibrosis that degrades the peritubular capillary 
network in mice following obstruction nephropathy (111;112). CD44s’s expression in 
damaged renal tissue is such that Kers et al. (2004) have used tubular CD44s 
expression as a surrogate marker for CAD-IFTA and estimated glomerular filtration rate 
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(eGFR) at 12 months post transplant (113). The functions of miR-204 targets implicate 
miR-204 down-regulation in increased levels of inflammation, apoptosis, and fibrosis. 
 
Table 3. miR-204 negatively correlated targets. Genes are according to their negative 
correlation to miR expression. The significance of the negative correlation is delineated 
by the p-value. The empirical p-value measures the statistical significance of the 
miR/mRNA pairings compared to a null distribution of randomized miR/mRNA pairings 
from the same data set (38). 
MicroRNA Probeset Gene Symbol 
Pearson 
Coefficient p-value 
Empirical 
p-value 
hsa-miR-204 219694_at FAM105A -0.873 9.64E-04 6.53E-04 
hsa-miR-204 221565_s_at CALHM2 -0.846 2.02E-03 1.44E-03 
hsa-miR-204 212796_s_at TBC1D2B -0.842 2.24E-03 1.67E-03 
hsa-miR-204 221530_s_at BHLHE41 -0.823 3.42E-03 2.58E-03 
hsa-miR-204 203320_at SH2B3 -0.822 3.53E-03 2.75E-03 
hsa-miR-204 212063_at CD44 -0.821 3.60E-03 2.88E-03 
hsa-miR-204 218870_at ARHGAP15 -0.817 3.88E-03 3.21E-03 
 
miR-211’s link to IFTA is not well understood, but like miR-204, miR-211 expression is 
down-regulated in IFTA. miR-211 is found on chromosome 15 and is associated with 
decreased invasion and metastasis of melanoma in addition to its epithelial functions 
and TGF-β modulation like miR-204 as stated earlier (101;114-117).  The mRNA IFTA 
signature genes that are most negatively correlated with miR-211 expression play roles 
in mitosis and mitogenic processes (38). Most interesting among these is dual 
specificity phosphatase 6 (DUSP6), a tumor suppressor that inhibits cytoplasmic ERK2, 
a key member of the MAP kinase cascade (118). Increased levels of DUSP6 impair cell 
invasion and EMT (epithelial-mesenchymal transition) while decreasing mitogenic 
activity and cell survival in cancer cells (118). It is reasonable to hypothesize that rising 
levels of DUSP6 secondary to decreased miR-211 expression will act as a 
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countermeasure to IFTA development in the chronically injured kidney, further 
complicating the relationship between these miRs and CAD with IFTA progression. 
 
Table 4. miR-211 negatively correlated targets. Genes are according to their negative 
correlation to miR expression. The significance of the negative correlation is delineated 
by the p-value. The empirical p-value measures the statistical significance of the 
miR/mRNA pairings compared to a null distribution of randomized miR/mRNA pairings 
from the same data set (38). 
MicroRNA Probeset Gene Symbol 
Pearson 
Coefficient p-value 
Empirical p-
value 
hsa-miR-211 219544_at C13orf34 -0.831 2.92E-03 1.65E-03 
hsa-miR-211 208891_at DUSP6 -0.814 4.15E-03 2.85E-03 
hsa-miR-211 203086_at KIF2A -0.79 6.54E-03 5.84E-03 
hsa-miR-211 203385_at DGKA -0.786 7.06E-03 6.78E-03 
hsa-miR-211 202241_at TRIB1 -0.783 7.45E-03 7.42E-03 
 
The relationship between these CAD with IFTA associated miRs and their in silico-
derived gene targets from mRNA CAD-IFTA signature paint a picture of these miRs as 
more than simple biomarkers, but potentially key factors in disease development. These 
relationships help shape the hypothesis that CAD-related miR expression directly alters 
renal cell function and viability in a manner consistent with CAD-IFTA development.  
This research seeks to evaluate the indicators of the renal allograft dysfunction in two 
ways: First, by affirming the pattern of miR expression in CAD-IFTA amongst an 
expanded and independent cohort of DDK recipients. Second, by evaluating the role 
miRs -142-3p, -204, & -211 play in the development of CAD-IFTA through studying the 
interactions between the CAD-IFTA associated miRs and their biologically relevant 
targets. Looking at CAD-related miR expression in a larger, more inclusive DDK 
recipient cohort will give greater insight into how these miRs reflect different clinical 
metrics of renal function. The established pattern of CAD-related miR expression in a 
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wider cohort will be a reflection of both poor clinical function (eGFR<60) and the 
presence of IFTA pathology. Studying the relationship between the CAD-related miRs 
and mRNA target expression in patients with CAD-IFTA will show that miR-142-3p, 
miR-204, & miR-211 are not just markers of CAD-IFTA, but also modulate genes that 
are important to the disease’s development. 
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Materials and Methods 
 
 
Urine Sample miR and mRNA Expression 
 
Urine cell collection and RNA isolation 
 
Urine samples (up to 100mL) were collected from the VCUHS Hume-Lee transplant 
clinic and centrifuged in 50mL Falcon® tubes at 3000 rpm for 20 minutes at room 
temperature to isolate the urine cell pellet. The supernatant was discarded, the pellets 
were re-suspended in 1mL of phosphate buffered saline (PBS) each, and transferred to 
1.5mL-microcentrifuge tubes.  The re-suspended pellet was spun for 5 minutes at 
10,000 rpm and the supernatant was completely removed from the washed pellet in 
preparation for RNA isolation or storage. For storage, the pellet was then re-suspended 
in 150μL of PBS and 500μL of RNAlater. The pellet was then stored at either 4oC for up 
to 24 hours or at -20oC for long term storage.  Upon thawing or removal from storage, 
500μL of cold (4-8oC) PBS was added to the urine cells in RNAlater before pelleting in a 
table top centrifuge at 13,300rpm for 5 minutes. The miRNeasy (Qiagen) RNA isolation 
kit was used to isolate RNA from both fresh and thawed urine cell pellets, according to 
their total RNA isolation protocol. RNA was eluted in 35μL of nuclease free water and 
stored at -80oC. RNA was quantified prior to use with the Qubit® RNA Assay kit and 
fluorometer (Life Technologies). 
 
31 
 
Reverse transcription: miR & mRNA 
 
Single tube miR reactions were performed to synthesize cDNA using the TaqMan 
MicroRNA reverse transcription kit (Life Technologies), according to the manufacturer’s  
protocol. Briefly, 10 ng of RNA (2 ng/μl) were combined with 3.0 μl 5X RT primer, 
0.15 μl 100 mM dNTPs, 1.0 μl MultiScribe Reverse Transcriptase (50 U/μl), 1.5 μl 10X 
RT buffer and 0.19 μl RNase inhibitor (20 U/μl) in a total reaction volume of 15 μl. 
Reactions were run on a 96-well plate at 16 °C for 30 min, 42 °C for 30 min and 85 °C 
for 5 min.  
Messenger RNA-cDNA synthesis were performed according to manufacturer's 
recommendation (Life Technologies). Briefly, RNA was reverse transcribed using the 
high capacity cDNA reverse transcription kit (Life Technologies) . 10μl of total RNA (2-
50 ng/μl) was combined with 2μl RT buffer (10X), 1μl MultiScribe Reverse Transcriptase 
(50 U/μl), 0.8μl dNTP mixture (25X), 2μL Random Hexamer primer (10X), and 1 μl 
RNase inhibitor (0.25 U/μl) in a total reaction volume of 20 μl. Reactions were run in a 
96-well plate at 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 min.  
 
miR & mRNA Expression 
 
The single tube miR expressions were detected using TaqMan chemistry according to 
the manufacturer's protocol (Life Technologies). 1.3 μl of cDNA were combined with 
0.25 μl 20X TaqMan MicroRNA assay and 5.0 μl 2X TaqMan Universal PCR MasterMix, 
No AmpErase UNG in a final volume of 10 μl. The reactions were run in triplicate in 384-
well plates on the 7900HT Real-Time PCR System according to manufacturer's 
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recommendations (Life Technologies). The raw fluorescence values were recorded by 
the SDS (Sequence Detection System) 2.3 software and converted into Cq values using 
the RQ (Relative Quantitation) Manager 1.2 software. PCR efficiency for each reaction 
was calculated by the LinRegPCR program (119). Expression of each miR was 
normalized against the geometric mean of 3 housekeeping small RNAs, RNU44, 
RNU48, and RNU66 using the Efficiency-ΔΔCt algorithm. These three RNAs were chosen 
because of their respective high, moderate, and low levels of stable expression in renal 
tissue and urine. Samples that failed to amplify these housekeepers (n=7) were 
excluded from analyses.  
Prior to gene expression analysis cDNA was diluted 1:3 and genes of interest were 
detected using TaqMan chemistry according to the manufacturer's protocol (Life 
Technologies). Each reaction included 1.5 μL diluted cDNA combined with 0.25 μL of 
20X TaqMan gene expression assay, and 5μL of TaqMan Gene Expression Master Mix 
(Life Technologies). The reactions were run in triplicate in 384-well plates on the 
7900HT Real-Time PCR System according to manufacturer's recommendations (Life 
Technologies). The raw fluorescence values were recorded by the SDS 2.3 software 
and converted into Cq values using the RQ Manager 1.2 software. PCR efficiency for 
each reaction was calculated by the LinRegPCR program. Gene expression was 
normalized against PPIA (peptidylprolyl isomerase) and GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) using the Efficiency-ΔΔCt algorithm. 
 
Statistical Approaches 
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The expression values were set to a normal distribution by exponential transformation, 
and the cohort average expression (approx. 1) was subtracted from the average 
expression in each patient group to plot the expression as an increase or decrease from 
the cohort average. Post-hoc F-tests were done to determine significant expression 
differences between CAD and normal allograft patient groups. One-way ANOVA was 
done to test the significant differences in expression between all the groups. All tests 
were considered significant at or below the  Bonferroni corrected p=0.0125, adjusting for 
the number of tests (0.05/4).  
Cell Culture miR and mRNA Expression 
 
RNA isolation 
 
HEK293 cells were loosened from culture dishes using trypsin, and  pelleted at 2,000 
rpm for 5 minutes. The trypsin and media were removed from the cell pellet; and the 
pellet was either resuspended in RNAlater for storage, or immediately isolated with the 
Ambion® mirVana RNA isolation kit (Life Technologies) using their total RNA isolation 
protocol. 
 
Reverse transcription: miR & mRNA 
 
In higher abundance (>90ng/ul) RNA samples, typically isolated from HEK293 cell 
culture, 10μL of each of the 5X RT primers tested (RNU44, RNU48, RNU66, miR-142-
3p, miR-204, & miR-211) were pooled into 60μL of nuclease free water and 880μL of 
Tris-EDTA (TE) buffer (pH 8.0) to make 1mL of pooled primers for up to 150 reverse 
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transcriptions. At least 350ng (approx. 90ng/μL) were added to 6μL of pooled 5X RT 
primers, 0.30 μl 100 mM dNTPs, 3.0 μl MultiScribe Reverse Transcriptase (50 U/μl), 
1.5 μl 10X RT buffer and 0.19 μl RNase inhibitor (20 U/μl) in a total reaction volume of 
15 μl. The reaction plating and temperature were the same as the low concentration 
miR reverse transcription above. 
Messenger RNA-cDNA synthesis were performed according to manufacturer's 
recommendation (Life Technologies). Briefly, RNA was reverse transcribed using the 
high capacity cDNA reverse transcription kit (Life Technologies) . 10μl of total RNA (5-
100 ng/μl) was combined with 2μl RT buffer (10X), 1μl MultiScribe Reverse 
Transcriptase (50 U/μl), 0.8μl dNTP mixture (25X), 2μL Random Hexamer primer (10X), 
and 1 μl RNase inhibitor (0.25 U/μl) in a total reaction volume of 20 μl. Reactions were 
run in a 96-well plate at 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 min.  
 
miR & mRNA Expression 
 
The pooled primer miR expressions were detected using TaqMan chemistry according 
to the manufacturer's protocol (Life Technologies). For each reaction 0.08μl of cDNA 
were combined with 0.25μl 20X TaqMan MicroRNA assay and 5.0μl 2X TaqMan 
Universal PCR MasterMix, No AmpErase UNG in a final volume of 10μl. The reactions 
were run in triplicate in 384-well plates on the 7900HT Real-Time PCR System 
according to manufacturer's recommendations (Life Technologies). The raw 
fluorescence values were recorded by the SDS 2.3 software and that data was 
converted into Cq values using the RQ Manager 1.2 software. PCR efficiency for each 
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reaction was calculated by the LinRegPCR program. Expression of each miR was 
normalized against the geometric mean of 3 housekeeping small RNAs, RNU44, 
RNU48, and RNU66 using the Efficiency-ΔΔCt algorithm. Samples that failed to amplify 
these housekeepers were excluded from analyses. 
Random hexamer cDNA was diluted 1:5 and genes of interest were detected using 
TaqMan chemistry according to the manufacturer's protocol (Life Technologies). Each 
reaction comprised 1.5 μL diluted cDNA combined with 0.25 μL of 20X TaqMan gene 
expression assay, and 5μL of TaqMan Gene Expression Master Mix (Life 
Technologies). The reactions were run in triplicate in 384-well plates on the 7900HT 
Real-Time PCR System according to manufacturer's recommendations (Life 
Technologies). The raw fluorescence values were recorded by the SDS 2.3 software 
and that data was converted into Cq values using the RQ Manager 1.2 software. PCR 
efficiency for each reaction was calculated by the LinRegPCR program. Gene 
expression was normalized against PPIA (peptidylprolyl isomerase) using the Efficiency-
ΔΔCq algorithm. 
 
Statistical Approaches 
 
The expression values were plotted as either increased or decreased from the cohort 
median, typically a value of 1. Paired t-tests between miR-transfected and empty vector 
control conditions were used to establish the significance of expression results, with 
p<0.05 as the threshold for significance.  
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Cloning Expression Plasmids 
 
miR sequences 
 
Primers were designed using the Ensembl browser 
(http://useast.ensembl.org/index.html) to identify the pre-miR sequence and  flanking 
DNA, and NCBI Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used 
to probe the DNA surrounding pre-miR sequence for primers. The primers were 
selected for specificity and size of gene product (Table 5).  
Table 5 - Primer sequences for miR-142-3p & miR-211. 
Primer Sequence  Product size 
miR-142-3p Forward 5'-CATGCTGAGTCACCGCCC-3' 484 bp 
Reverse 5'-TCAGGGTTCCACATGTCCAG-3' 
miR-211 Forward 5'-TGATGCTGCAGAGTGGGTAG-3' 475 bp 
Reverse 5'-GACATGCATTGAGGGTCTGC-3' 
 
Restriction enzyme sequences were added to the primers to allow for sequence 
selection and efficient cloning. A Sac-I site (5’-GAGCTC-3’) was added to the 5’ end of 
the forward primer, while a BamH-I restriction site (5’-GGATCC-3’) was added to the 3’ 
end of the reverse primer. The 25 nanomoles of lyophilized and desalted primers were 
made by Invitrogen. The primers were diluted to 20μM with TE (pH = 8.0) before being 
used in a gradient PCR using the Immolase PCR kit (Bioline) according to the 
manufacturer’s  recommended protocol. Upon finding the optimum PCR temperature, 
genomic DNA was probed to produce the pre-miR sequence. The pre-miR sequence 
was size selected on an agarose gel and the DNA was digested using Sac-I (New 
England Biolabs, NEB) and BamH-I (NEB) to produce cohesive ends. The same 
cohesive ends were produced on the pmR-ZsGreen expression plasmid, and the pre-
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miR sequence was ligated into the pmR-ZsGreen (4714bp) plasmid using T4 Ligase 
(NEB) according to their 3:1 molar ratio formula and recommended experimental 
conditions. Challenges with cloning the pre-miR-204 sequence necessitated ordering 
the 162bp pre-miR-204 sequence with the Sac-I and BamH-I cohesive ends from 
Eurofins/Operon in the PCR-2.1 vector (Table 6). The pre-miR-204 was cut out of the 
PCR-2.1 plasmid and ligated into the pmR-ZsGreen in the same manner as the PCR 
products mentioned above.  
Table 6. pre-miR-204 sequence with cohesive ends. Restriction sites are underlined and mature 
sequence in bold. 
Name Sequence Size 
miR-204 
Sac+Bam 
5’-TATAGAGCTCTGATCGCGTACCCATGGCTACAGTCTTTC 
TTCATGTGACTCGTGGACTTCCCTTTGTCATCCTATGCCTG 
AGAATATATGAAGGAGGCTGGGAAGGCAAAGGGACGTTCA 
ATTGTCATCACTGGCATCTTTTTTGATCATTGGGATCCTATA 
 
(162 bp) 
  
All cloned plasmids were transformed into E. Coli by heat shocking the bacteria in 
medium seeded with the newly ligated pre-miR-ZsGreen. The transformed bacteria 
were grown overnight on kanamycin-selective agar plates. Colonies from the selective 
plate were amplified in liquid medium for 16-24 hours, after which their DNA was 
collected using the Qiagen Mini-Prep DNA Isolation Kit (Qiagen) according to their 
recommended protocol. DNA concentration was measured by nanodrop. The DNA was 
then digested and gel purified to verify the presence of the cloned insert. All cloned 
sequences were verified by the Nucleic Acid Research Facility (NARF) and Virginia 
Commonwealth University.      
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3’-UTR sequences 
 
Eight 3’-UTR sequences were cloned into the pmiR-Glo dual luciferase vector 
(Promega), the 4 miR targets of interest: TMEM14A (142-3p), CD44 (miR-204), 
BHLHE41 (miR-204), & DUSP6 (miR-211); 3 genes that are known targets for each 
miR:  ADCY9, BCL2L2, & TGF-βR2; and one nonsense sham sequence (Table 7). 
These sequences contain the miR seed sequence and 70bp flanks up- and downstream 
of the seed sequence. Each of these sequences was ordered from Eurofins/Operon in 
the PCR-2.1 expression plasmid. The plasmids were amplified by the same mini-prep 
procedure described above, and digested with Sac-I and Xba-I (NEB) to make the 3’-
UTR insert with cohesive ends. These inserts were individually ligated into the pmiR-Glo 
plasmid and grown using a mini-prep procedure. The DNA was then digested to verify 
the presence of the insert and the cloned sequences were verified by the NARF at 
Virginia Commonwealth University. 
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Table 7. Target 3'-UTR Sequences. Seed complements in red 
miR Target Sequence 
miR-142-3p 
TMEM14A 
5'-GCGATCGCCAGTTATGTCTGGGATGTTTTAATCCT 
CCAAGGGGTTGAGCTGGGAGAGCCCCCAAGCCAAG 
GATTAGTAACACTACTGGGTAGGCGAGTGCATGGCC 
CTTTCTGTCTTATGCCAGATAAAAGTGACTCTCCCTTT 
GTCTTTGCTCGAG-3' 
ADCY9 
5'-GCGATCGCGGTTGTGACAATACCTCTTGCTTCTAA 
AGAATGTATTATAAAACACCGCAGATTTTTTTTTTTCC 
TTAAAAAACACTACCTGATGCTTTCCTTGTTCGTGGG 
GATTGTGGTCACATGAAGCTCTTTCTGCATCAGTATT 
AAGGTGTATATTCTCGAG-3' 
miR-204 
BHLHE41 
5'-GCGATCGCAGAGTGAGAAGTTAAAATACCCTTAAG 
GAGGTTCAAGCAGAGTGAGAAGTTAAAATACCCTTAA 
GGTCTTTAAGGGAGGAAGTGTAATAGATGCACGACA 
GGCATAAACAAGAACAACAAAACAGGTGTTATGTGTA 
CATTCGGAGTTCTCGAG-3' 
CD44 
5'-GCGATCGCCAGTGTCTGTTCTTGATGCAGTTGCTA 
TTTAGGATGAGTTAAGTGCCTGGGGAGTCCCTCAAAA 
GGTTAAAGGGATTCCCATCATTGGAATCTTATCACCA 
GATAGGCAAGTTTATGACCAAACAAGAGAGTACTGGC 
TTTATCCTCTAACTCGAG-3' 
BCL2L2 
5'-GCGATCGCAAATAAGGGAAATAAATGTAATTGCCA 
TTTTTCAAAGATTAAGTAGGAGGAGAGGGGTTTCTTG 
CTCTCCAGAGCCCAAAGGGACAAATAGGGACTTTGT 
TTAGGCCAAGGAAGGAGCGGAAGTAGGGCAACTCG 
GTCCTGCGATTATTAATCCCACTCCCTCGAG-3' 
miR-211 
DUSP6 
5'-GCGATCGCCTTGAATCACTTGACAGTGTTTGTTTG 
AATTGTGTTTGTTTTTTCCTTTGATGGGCTTAAAAGAA 
ATTATCCAAAGGGAGAAAGAGCAGTATGCCACTTCTT 
AAAACAGAACAAAACAAAAAAAGAAAATTGTGCTCTT 
TTCTAATCCAACTCGAG-3' 
TGFBR2 
5'-GCGATCGCTTATTCAAGAAAAAAGACCAAGGAATA 
ACATTCTGTAGTTCCTAAAAATACTGACTTTTTTCACT 
ACTATACATAAAGGGAAAGTTTTATTCTTTTATGGAAC 
ACTTCAGCTGTACTCATGTATTAAAATAGGAATGTGAA 
TGCTATATACTCTTCTCGAG-3' 
 Sham 
5’-GCGATCGCCCTGGCCCTCTTCCATAACTGCGGTTA 
GACCTCCGCATAGATCTCCGTCCCCGCTCCCCTCTG 
GAGTACGATTCAAGTGTGCGCAGATTAAGTCATTATC 
GAACCTAGAGCATACTGGTTGCGTAGGGGTTATTGCA 
GTAAGCCAAAAGTCTCGAG-3’ 
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Transfection 
 
Six-well plates 
 
Transfections for miR and gene expression assays were done in 6-well plates. 
Approximately 700,000 HEK293 cells were plated in each well in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS) without antibiotics 24 
hours before transfection. The cells were over 90% confluent at the time of transfection. 
The pre-miR plasmid or empty vector controls were diluted into 250μL of Opti-MEM 
without serum while Lipofectamine 2000 (Invitrogen) was diluted into 250μL of Opti-
MEM without serum. The volume of lipofectamine was determined by a 1:3 ratio of 
micro-liters of lipofectamine to micrograms of DNA transfected. The individual Opti-
MEM solutions are incubated at room temp for 5-10 minutes before being combined to 
make 500uL of DNA and lipofectamine in Opti-MEM. The new solution is incubated at 
room temperature for 30 minutes to allow the lipofectamine to complex with the DNA. 
The 500μL of DNA-Lipofectamine solution is added to 2.5mL of media without 
antibiotics and the reactions were incubated at 37oC for 24 hours, after which the cells 
were collected and their RNA isolated. 
 
96-well Plates 
 
Transfections for luciferase assays were done in 96 well plates. Each reaction condition 
was transfected in triplicate. In each reaction, 75,000 HEK293 cells were seeded in 
each well 24 hours prior to transfection. For each reaction, 10ng of pre-miR plasmid or 
empty vector control, 6.67ng of pmiR-Glo from a target of interest or sham control, and 
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where applicable, 10pmol of anti-miR inhibitor or negative control (Ambion) were diluted 
in Opti-MEM without serum to 25 μL. Likewise 0.3μL of Lipofectamine 2000 was diluted 
into 24.7 μL of Opti-MEM without serum. After room temperature incubations of 5 
minutes individually, and 30 minutes together, 50 μL of the DNA-Lipofectamine solution 
is plated onto cells in 100 μL of media without antibiotics and the reaction goes on for 
24 hours at 37oC after which, cells are examined for the fluorescent marker of the pre-
miR plasmid and harvested. 
 
Luciferase Assays  
 
The luciferase assays were done according to the Dual-Glo® Luciferase Assay 
(Promega) microplate procedure. First, the medium on the cells was removed from each 
well and replaced with 75 μL of medium without antibiotics. After equilibrating to room 
temperature, 75 μL of the Dual-Glo® Luciferase reagent is added to the cells in media. 
The entire mixture is agitated by pipetting to aid lysis and the mixture is transferred to 
the Lumitrac 200 96-well luminometer plate (Greiner® Bio-One). The lysed cells were 
incubated in the luciferase reagent for 10 minutes and then firefly luciferase activity was 
measured in a Wallac Victor II luminometer (PerkinElmer). Next, 75 μL of Dual-Glo® 
Stop & Glo® Reagent (1 μL substrate : 100 μL buffer) is added to each well and mixed 
by pipetting. After a 10 minute incubation, the renilla luciferase activity was measured. 
Background correction was done by subtracting the average firefly luciferase reading of 
mock transfections (Lipofectamine and cells only) from the raw firefly luciferase 
measurements and doing the same with the raw renilla readings. The ratio of firefly to 
renilla (L/R) was taken for each well and the average of the triplicates for each condition 
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was taken. The ratios were corrected to a percentage of empty vector control 
expression, or in the case of the anti-miR, negative control expression. The normalized 
ratios were then plotted relative to the luminescence of the corrected miR-sham control 
pairing. A paired Student’s t-test was used to calculate significant mean differences 
between each condition and its sham control.  
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Results & Discussion 
 
 
Donor Quality and Gene Expression in Delayed Graft Function 
 
DGF is a purely clinical diagnosis with no chemical or molecular measure. DGF is 
loosely defined as the recipient’s need for dialysis during the 1st post-operative week. Its 
development is linked to hypoxia and ischemia reperfusion injury. An examination of a 
VCUHS patient cohort of deceased donor kidney (DDK) recipients (n=147) showed that 
poor donor quality (Table 8) is also associated with DGF. Our patient cohort had 54 
DDK recipients (36.7%) diagnosed with DGF. Grossly, the distribution of DGF 
diagnoses was split evenly between standard criteria donors (SCD) and extended 
criteria donor/donations after cardiac death (ECD/DCD) (Table 8). However, as a 
percentage of patients within the specific donor quality groups, only 27.1% of SCD 
recipients were diagnosed with DGF, 50% of ECD, and nearly 60% of DCD patients 
within our patient cohort were diagnosed with DGF (Table 5). Donor quality is also 
significantly associated with use of perfusion pumps, where 70.8% & 81.5% of poor 
quality kidneys received pump treatment compared to less than half of SCD kidneys 
(Table 5). Perfusion pumps are used to both preserve and, in some cases, test the 
quality of the donor organs (18;19). The use of perfusion pumps in our patient cohort 
was not associated with a statistically significant decrease in DGF diagnosis. 
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Table 8. DGF diagnoses amongst 147 DDK recipients according to donor quality and pump 
use. Significance was determined by Chi-squared analyses of Donor Quality vs DGF & Pump 
use >360 minutes. *p-value <0.0028 to account for multiple testing 
Donor Quality no DGF DGF Totals %DGF %Pump no pump Pump no pump 
SCD 33 37 9 17 96 27.1* 47.9* 
ECD 4 8 9 3 24 50.0* 70.8* 
DCD 0 11 11 5 27 59.3* 81.5* 
Totals 37 56 29 25 147 36.7 57.8 
%SCD 89.2 66.1 31.0* 68.0 α = 0.0028 
%ECD 10.8 14.3 31.0* 12.0 df = 6 
%DCD 0.0 19.6 37.9* 20.0 
 
Clinical data on donor quality affirms a link between donor quality and DGF 
development. Gene expression analysis of DGF was done to compare expression in 
DGF vs. normal function, assess the effects of reperfusion, and look at post operative 
changes that may result in DGF.  A total of 118 biopsy tissue samples from 59 DDKs 
taken pre-implantation (K1) and 60 minutes post-perfusion (K2) shows differential 
expression of 146 genes in patients with DGF compared to those without DGF. 
IngenuityTM pathway analysis of these genes show a picture of DGF as both an anti-
inflammatory response, with up-regulation of genes like SOCS1 (suppressor of cytokine 
signaling 1), and anti-proliferative with increased expression of tumor suppressor MZF1 
(myeloid zinc-finger protein 1) & PDE4B (cAMP-specific phosphodiesterase); and 
decreased expression of the mitogenic signal transducer, PI3K (phosphoinositol-3-
kinase) (Fig. 5).   
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Figure 5. Ingenuity generated network of DGF associated genes, down-reglated genes in green, up-
regulated genes in red. Down-regulated genes include PI3-K complex, RTK2, & ABCA1. Up-regulated 
genes include SOCS1, PDE4B, & APOBEC3A 
Further analysis of genes expressed in both the K1 and K2 samples was done to 
develop a perioperative gene expression pattern associated with DGF. Comparing array 
data from 91 K1 samples of patients with DGF to those without showed 190 
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differentially expressed genes. A  similar comparison of DGF vs. no-DGF expression in 
37 K2 samples resulted in 127 differentially expressed genes. A ToppGene analysis of 
the 190 genes differentially expressed in K1 samples with DGF and the 127 genes 
differentially expressed in K2 samples with DGF showed 18 genes with common gene 
expression in the 2 cohorts (Fig. 6A). While these 18 genes were not mapped to a 
particular biological process, the gene expression signature (Fig. 6B) of this analysis 
shows the potential to be either predictive or diagnostic for DGF perioperatively.   
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A 
 
B 
Figure 
6. ToppGene analysis of differentially expressed genes in DGF. (A) Diagram of commonly expressed 
genes in K1 DGF vs. no-DGF (190) and K2 DGF vs. non-DGF (127). (B) Differential expression of DGF 
vs. non-DGF genes commonly expressed in K1 (pre-implantation, blue) and K2 (post-reperfusion, yellow) 
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To analyze the effect on reperfusion and examine the genes implicated in ischemia 
reperfusion injury, the differential gene expression was compared between the K1 and 
K2 samples from patients that developed DGF. IngenuityTM gene ontology analysis of 
the differentially expressed genes showed an up-regulation of several inflammatory 
processes (Fig. 7). The activation of these cellular processes present an interesting 
juxtaposition with the miRs that have altered expression in ischemia reperfusion injury. 
Of particular interest is miR-21, which is both up-regulated in IRI models (40;86;88;89), 
and directly targets PPARα in murine models of renal fibrosis (41). The abrogation of 
the PPARα signaling leads to higher levels of COX2 (cyclooxygenase 2) and production 
of pro-inflammatory prostaglandins (Fig. 8).  Alterations of inflammatory signaling seen 
in DGF may be attributed to miR-21 activity as well as other miRs indicated in IRI, 
including miR-142-3p (40;86;88;89), meaning that these miRs could be activating the 
inflammation of IRI or perpetuating a positive feedback loop resulting in the chronic 
inflammation that sets the stage for CAD with IFTA. Overall, these results further 
characterize the kidney’s reaction to recipient reperfusion, and situate ischemia 
reperfusion injury as a hyper-inflammatory state that can potentially trigger tissue death 
and fibrogenesis.   
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Figure 7. Gene ontology for delayed graft function comparing pre-implantation vs. post-reperfusion. 
Statistically significant (q < 0.05) differentially expressed genes were analyzed for their presence in 
canonical pathways. A Fisher’s exact test was used to calculate the p-value of the comparison between 
the proportion of differentially expressed genes within a pathway in the K2  dataset to the proportion of 
differentially expressed pathway genes in the K1 dataset. Blue bars represent the negative logarithmic 
values of the significance level beyond the threshold of p = 0.05. Orange points represent the log-
transformed ratio of the number of differentially expressed genes in the pathway to the total number of 
genes in the pathway. 
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Figure 8 – IngenuityTM PPAR signaling canonical pathway, annotated with differential expression 
from IRI study. Down-reglated genes in green, up-regulated genes in red. Note the up-regulation of the 
inducible inflammatory enzyme COX2 and its transcription factors, c-Fos & c-Jun. 
Array data from post-perfusion (K2) biopsy tissue from the 59 DDK recipients comparing 
patients with DGF to those without DGF, showed 673 differentially expressed genes. 
Gene ontology shows the differentially expressed genes from this cohort are associated 
with both pro- and anti-apoptotic processes (Fig. 9). Network analysis shows the 
expression pattern of these genes is consistent with increased cell survival, but 
decreased proliferation (Fig. 10). Up-regulation of MAP-kinases, purine metabolism 
enzymes (adenosine deaminase & adenosine phosphoribosyl transferase), translation 
initiators (EIF4EBP2), transcription activators (CDK8) are all consistent with cell 
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survival. However, up-regulation of PTEN (phosphatase and tensin homolog), which 
initiates cell cycle arrest, coupled with down-regulation of actin depolymerizers (LIMK1-
2), glucose transporters, and anti-apoptotic proteins like Bcl-3, shows a cell that is 
decidedly not mitogenic. The impression from these expression patterns illustrates that 
the post-reperfusion kidney tissue in DGF is mounting a response to the stress of IRI, 
but that response is not robust, or directed toward cell survival and normal proliferation 
enough to stave off post-operative dysfunction. 
 
Figure 9. Gene ontology for K2 samples (n=59) DGF vs. no-DGF. Statistically significant (q < 0.05) 
differentially expressed genes were analyzed for their presence in canonical pathways. A Fisher’s exact 
test was used to calculate the p-value of the comparison between the proportion of differentially 
expressed genes within a pathway in the K2-DGF dataset to the proportion of differentially expressed 
pathway genes in the K2-non-DGF dataset. Blue bars represent the negative logarithmic values of the 
significance level beyond the threshold of p = 0.05. 
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Figure 10. Ingenuity™ network from K2 array data comparing DGF to no-DGF. Down-reglated genes in 
green, up-regulated genes in red. 
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In summary, the gene expression patterns validate the clinical findings resulting from 
the organ transplantation at a molecular level, thus having important early prognostic 
value, i.e. a kidney  without blood flow experiences inflammatory and pro-apoptotic 
stresses that can be mitigated upon reperfusion. The ability of the tissue to mount and 
then abrogate and appropriate inflammatory response followed by cell growth and 
proliferation might be the driving forces behind whether or not the implanted kidney 
tissue will begin to function properly, or will scar and eventually lose its functionality.  
While not completely predictive of graft failure, the molecular changes seen in the early 
modes of transplant dysfunction indicate the beginnings of the chronic dysfunction 
results in renal transplant loss.   
 
Independent validation of CAD-related microRNA expression in urine samples 
 
Research previously published work by Scian and colleagues (2011) had shown that 56 
tissue-specific miRs are associated with the development of IFTA. (38).  Specifically, 
genome wide miR expression profiles of IFTA were generated on Illumina BeadChip 
arrays using total RNA isolated from a biopsy tissue from 18 deceased donor transplant 
recipients, 13 of whom were diagnosed with IFTA, during the first year of their cadaveric 
renal transplants. In this study, the authors found that miR-32, miR-107, miR-142-3p, 
miR-204, and miR-211 were the top differentially expressed miRs. Our microarray 
results were validated on the same samples using the real time PCR approach. 
Furthermore, the expression of these miRs was tested in an additional 27 biopsies, 19 
of which had diagnosed IFTA, and  paired urine samples from 7 patients with IFTA and 
7 with normal allograft function (NA). We observed excellent agreement in the 
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expression of miR-142-3p, miR-204, and miR-211 between biopsies and urine samples 
(38).  The validation of miR expression was analyzed using RNU48 as an endogenous 
control for normalization.  Fold change was calculated from threshold cycle (Ct) values 
using the ΔΔCt method with the equations below: 
Equation 2. Fold change = 2-ΔΔCt 
Equation 3. ΔΔCt = ΔCt of IFTA – ΔCt of NA (38). 
 Hierarchical clustering of urine samples ΔCt values was done in a prospective 
validation set of 108 urine samples from 36 DDK transplant recipients where each 
patient provided a urine sample at 3,9, and 12 months post transplant (38). The 
clustering validated the pattern of miR expression associated with IFTA. The 
approaches done in previous work evaluating CAD-related miR expression assessed 
miR-142-3p, miR-204, and miR-211 as biomarkers of CAD-IFTA, but did not truly delve 
into their role in disease development. An independent validation of CAD-related miR 
expression in a larger more varied DDK recipient cohort, using more stringent methods 
of evaluating differential expression, is the first step in elucidating the role these miRs 
play in the development or progression of CAD-IFTA. 
An independent verification of CAD-related miR expression was done using RT-qPCR 
of 155 urine samples from 134 patients collected from discarded urine samples. The 
sample cohort was divided into 4 categories based on renal dysfunction and histo-
pathologically diagnosed IFTA (Table 9). Renal dysfunction is defined as a creatinine-
based eGFR < 60 ml/min/1.73m2 at the time of sample collection because that is the 
threshold for sufficient single-kidney function post transplant (11;12). IFTA is defined as 
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Banff Category 5 grades 0-3, where the presence of any Banff Category 5 diagnosis 
qualifies as present (Table 9). 
Table 9 - Sample cohort classifications. The cohort was divided into 4 groups based on their renal 
function as assessed by eGFR and any diagnosed interstitial fibrosis and tubular atrophy (IFTA). Group 1 
(CAD-IFTA) is associated with the worst renal function and graft prognosis, and is the focal diagnosis of 
these studies. 
Grou
p Name eGFR 
IFTA 
pathology 
Renal 
Function/Prognosis 
1 CAD-IFTA <60 ml/min/1.73m2 Present Worst 
2 Renal Dysfunction 
<60 
ml/min/1.73m2 Absent Poor 
3 IFTA >60 ml/min/1.73m2 Present Adequate-Poor 
4 Normal Allograft >60 ml/min/1.73m2 Absent Good-Adequate 
 
The geometric mean of 3 endogenous controls, RNU44, RNU48, and RNU66 was used 
for normalization. Relative expression was calculated from threshold cycle (Ct) values 
using the ΔΔCt method with the equations below: 
Equation 4.  ΔΔCt = ΔCt of Sample – median ΔCt of cohort 
Equation 5. Relative Expression = Efficiency-ΔΔCt  
The PCR efficiency was determined using the LinRegPCR program that utilizes the 
Log(fluorescence) per cycle from qPCR experiments to make a linear regression model 
that calculates the PCR efficiency of each reaction (119). This method proves for a 
more accurate assessment of measuring relative expression rather than assuming an 
efficiency of 2. Calculating the relative expression of the miRs using a ΔΔCt value 
based on the cohort median offers two advantages: 1) minimizes  the potential bias 
introduced by outlying PCR reactions  and 2) provides an individual expression value for 
each sample. The relative expression values for each gene in the sample were further 
56 
 
assessed for normality by the Kolmogorov-Smirnov test and genes whose expression 
deviated from normal distribution, were exponentially transformed to approximate 
normal distribution. Prior to the actual analyses, the normalized expressions of miR-
142-3p, -204, and -211 were fitted into a forward step-wise regression model to assess 
the impact of potential demographic covariates (i.e. age, sex, race, donor quality) on the 
expression of these molecules. These covariates had no significant effect on the 
expression of miR-142 (ANOVA df=7, F=1.67, p=0.12), miR-204 (ANOVA df=7, F=1.72, 
p=0.11) and miR-211 (ANOVA df=7, F=0.46, p=0.86) and therefore were not included in 
the main analysis.  
The urine samples from group 1 (CAD with IFTA) showed up-regulation of miR-142-3p 
and down regulation of miR-204 and miR-211 compared to normal allograft (Fig. 11). 
The samples from group 2 (eGFR<60 ml/min/1.73m2) showed decreased expression of 
all the CAD-related miRs. The samples from group 3 (IFTA pathology) showed an up-
regulation of miR-204 and miR-211, and a down-regulation of miR-142. The samples 
from the normal allograft group (group 4) showed a down-regulation of miR-142-3p, and 
up-regulation of miR-204 and miR-211 compared to the CAD-IFTA group (Fig. 11). 
Each miR’s expression was analyzed by one-way ANOVA to assess the significance of 
the differential expression between groups. miR-142-3p (df=3, F=2.91, p=0.036) 
showed a significant expression differences between the patient groups.  Post-hoc F-
tests were done to assess significant differences between the patient groups. A 
Bonferroni correction for multiple testing lowered the threshold for significance, α, to 
0.0125 (0.05/4), and  we observed differential miR-204 expression between  group 1 
(CAD-IFTA) and group 3 (IFTA only) (p=0.009). A similar difference in miR-204 
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expression was observed between the CAD-IFTA group and the normal allograft group 
(p=0.0104). A difference in miR-211 expression was also seen between the CAD-IFTA 
group and normal allograft group (p=0.0037) 
 
Figure 11 - Relative expression of CAD-related miRs in urine samples of transplant recipients. 
Relative expression values were exponentially transformed to approximate a normal distribution. The 
normally distributed expression values were then plotted using the cohort average as the origin to show 
how each miR in each condition deviated from the cohort average.  
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Table 10 - Demographic and clinical data from patients in miR expression analysis. 
Percentages are in parentheses 
CAD+IFTA NA eGFR<60 IFTA 
Patients 31 46 57 20 
Age 47.00 + 12.43 52.94 + 12.77 
53.19 + 
12.56 
50.73 + 
12.02 
Sex       
Male 11 (35.5) 27 (58.7) 35 (61.4) 13 (65.0) 
Female 20 (64.5) 19 (41.3) 22 (38.6) 7 (35.0) 
Race       
Black 23 (74.2) 37 (80.4) 35 (61.4) 11 (55.0) 
Caucasian 5 (16.1) 8 (17.4) 16 (28.1) 6 (30.0) 
Hispanic 2 (6.5) 0 4 (7.0) 3 (15.0) 
Asian 1 (3.2) 1 (2.2) 2 (3.5) 0 
Donor Quality       
SCD 19 (61.3) 34 (73.9) 27 (47.4) 11 (55.0) 
ECD 8 (25.8) 1 (2.2) 15 (26.3) 2 (10.0) 
DCD 3 (9.7) 8 (17.4)) 12 (21.0) 3 (15.0) 
Other/Unknown 1 (3.2) 3 (6.5) 3 (5.3) 4 (20.0) 
DGF?       
Yes 13 (41.9) 20 (43.5) 33 (57.9) 11 (55.0) 
No 18 (58.1) 22 (47.8) 23 (40.4) 9 (45.0) 
Unknown 0 4 (8.7) 1 (1.7) 0 
IFTA Grade 
0/1/2/3 
18/4/4/5 
(58.1/12.9/12.9/16.1) n/a n/a 
8/12/0/0 
(40.0/60.0/0/0) 
Avg. Serum 
Creatinine (mg/dL) 2.33 + 1.01 1.03 + 0.21 1.76 + .051 1.10 + 0.24 
Avg. Estimated 
GFR 35.26 + 13.65 
82.22 + 
19.69 43.96 + 9.53 
74.03 + 
12.28 
 
The expression of the selected CAD-related miR targets: TMEM14A (for miR-142-3p), 
CD44 & BHLHE41 (for miR-204), and DUSP6 (for miR-211), was assessed in the urine 
samples of 57 DDK patients via RT-qPCR. Of the 4 genes tested, CD44 showed a 
significantly different expression (one-way ANOVA, df=3, p=0.007) in patients with 
CAD-IFTA compared to normal allograft patients (Fig. 12). The CD44 expression affirms 
the findings of Kers et al. who showed that CD44 expression is a marker of IFTA and 
decreased graft survival (109-113). Our findings indicate that CD44 expression is 
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highest in the combination renal dysfunction, but also elevated in the presence of IFTA 
pathology alone. This pattern is particularly the case in simple renal dysfunction (eGFR 
<60 ml/min/1.73m2), whose CD44 expression is not significantly different from patients 
with normal allografts (F-test, p=0.26), while patients with only IFTA pathology have 
some increased CD44 expression, but not to the degree of patients with CAD-IFTA. The 
other gene target-miR pairings showed a trend of anti-correlation characteristic of 
canonical miR function, but their expression differences did not meet statistical 
significance.  
 
Figure 12 – CD44 Expresssion in Urine Samples. 57 of 60 patient urine samples passed quality control 
and relative expression of CD44, BHLHE41 (not shown), DUSP6 (not shown),  and TMEM14A (not 
shown) were assessed via RT-qPCR. Relative expression values were corrected to a normal distribution 
and average expression for each patient group was adjusted to the cohort average. * = p-value < 0.05 
The increased CD44 gene expression coupled with the decreased miR-204 expression 
(Fig. 11) in the urine samples of patients with CAD-IFTA further indicate a role for miR-
204 in the development of CAD-IFTA through targeting of the CD44 molecule. The 
relationship between the expression of CD44 and miR-204 is negatively correlated in all 
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patient groups While the BHLHE41, DUSP6, and TMEM14A expression differences 
between patient groups was not as pronounced as seen in CD44, they also showed a 
trend of negative correlation between their expression and miRNA expression. This 
trend of anti-correlation between CAD-related miRs and their targets indicates a 
potential interaction between these miRs and their proposed targets. These findings, 
especially the CD44 expression, provide another potential molecular metric of chronic 
renal allograft dysfunction, and establish a basis for further study of the direct 
relationships between the CAD-related miRs and their predicted targets.  
 
Assessment of the Novel Targets of CAD-Related microRNAs 
 
Novel targets for the CAD-related miRs were derived from an in-silico analysis of miR 
and mRNA arrays comparing patients with and without CAD-IFTA. The differentially 
expressed miRs and mRNAs were correlated to identify regulation patterns consistent 
with miR-mediated changes in gene expression (Tables 3-5). Genes that were in silico 
predicted and anti-correlated with miR-142, -204, and -211 (Appendices A-C) in the 
urine samples of subjects with CAD-IFTA were selected for experimental validation in 
HEK293 cells. The pre-miR sequence of each CAD-related miR was cloned into the 
pmR-ZsGreen microRNA expression vector and transfected into HEK293 cells to 
simulate over-expression of each miR (Figs. 13-14). Over-expression of the CAD 
related miRs in the HEK293 was assessed using RT-qPCR (Figs. 14-15).  
  
61 
 
A 
 
B 
Figure 
13 - Schematic of pmR-ZsGreen (A) and DNA gel picture of pre-miR inserts and open pmR-
ZsGreen (B) used for cloning. The Inserts for miRs-142-3p (484bp), miR-204 (572bp), & -211 (475bp) 
were cut from TOPO PCR 2.1 vector using SacI & ApaI restriction enzymes, and cloned into the multiple 
cloning site of pmR-ZsGreen. Cloning was confirmed by selective digestion following bacterial 
transformation, growth and expansion in selective media 
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Figure 14 - Transfection efficiencies. Average transfection efficiencies for  pmR-ZsGreen plasmid 
transfection by transfected DNA weight. EV-empty vector. 
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A 
 
B 
 
C 
 
Figure 15 - MicroRNA overexpression in HEK cells. Relative expression measured by RT-qPCR for miR-142-3p 
(A), miR-204 (B), and miR-211 (C) all compared to their respective empty vector (EV) controls. Student’s t-test used 
to assess significance (p < 0.05) between miR-transfected and EV control cell groups. These experiments show the 
cells’ ability to produce mature microRNA from increasing amounts of pre-miR plasmid, and confirm the function of 
the cells transcriptional machinery in the presence of exogenous DNA. * = p < 0.05 
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Cells with miR over-expression were also evaluated for mRNA target expression using 
RT-qPCR. The miR-target pairings tested were: miR-142-3p with TMEM14A, miR-204 
with CD44 molecule & BHLHE41, and miR-211 with DUSP6. Cells over-expressing 
miR-142-3p showed a decrease in expression of both TMEM14A mRNA relative to 
untransfected controls (Fig. 16A). Cells over-expressing miR-204 showed a decreased 
expression of BHLHE41 and CD44 compared to controls (Fig. 16B-C). Cells over 
expressing miR-211 did not exhibit the same type of decreased expression of DUSP6 
as the other miR-target pairings tested via over-expression. The targets for miR-211 
consistently showed increases in mRNA expression compared to controls with 
increasing levels of miR-211 present in the cell (Fig. 16D). This deviation from the 
expected expression pattern may indicate an unexpected relationship between miR-211 
and its targets, or, more likely, give insight to how miR-211’s actions balance between 
stabilizing mRNA and triggering mRNA degradation. 
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A      B 
  
C      D 
  
Figure 16 - mRNA expression of proposed CAD-related miR targets following miR overexpression 
in HEK293 cells. Gene expression with increasing amounts of transfected miR-142-3p (A), miR-204 (B-
C), and miR-211 (D). Expression presented is relative to untransfected controls. miR-142-3p and miR-204 
targets show  decreased expression compared to cohort median (A-C), while DUSP6 expression 
increases with miR-expression. * = p < 0.05 
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The changes in gene expression when following miR overexpression in HEK293 cells 
indicate that the miRs-142-3p and -204 are decreasing the expression of their 
prospective target genes, while miR-211 overexpression drives an increase in its 
prospective target, DUSP6, compared to controls. While the miR-target relationship 
between miRs-142-3p and -204 and their respective targets follows the canonical model 
of miR function, the exact nature of the miR-211-DUPS6 hybridization may result in 
more stabilization or even translational activation rather than mRNA degradation. The 
gene silencing may trigger a feedback mechanism to increase transcription of DUSP6. 
Increased mRNA production coupled with the miR-211-DUSP6-mRNA duplexes not 
being degraded could result in greater detection of DUSP6 transcripts once those 
duplexes are melted during the RT-qPCR reactions.  
Luciferase assays were performed in order to establish the specificity of the relationship 
between the CAD-related miRs and their targets. The 3’-untranslated region (3’UTR) for 
each of the target genes specified above, along with a sham control sequence, and a 
panel of established gene targets for the CAD-related miRs were individually cloned into 
the pmiR-Glo dual luciferase plasmid (Promega). The established targets comprised of: 
adenylate cyclase 9 (ADCY9), a miR-142-3p target (97); BCL2-like2 (BCL2L2), a miR-
204 target (102;103); and TGFβR2, a miR-211 target (100). HEK cells grown on a 96-
well plate were co-transfected for 24 hours with the luciferase plasmid containing a 
3’UTR sequence and a miR-mimic plasmid. Each miR-target pairing was done in 
triplicate along with relevant controls including a sham 3’UTR sequence and empty 
vector controls. Additionally, 10nM of antimiR microRNA-inhibitor (or control) 
oligonucleotides were also transfected to block the miR-target binding in the cells. The 
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experimental results show that miR-142-3p blocked luciferase production by binding the 
3’UTR of its target, TMEM14A.  The miR-142-3p interaction with TMEM14A produced a 
13.7% decrease in luciferase production compared to a sham sequence control. The 
inhibition of luciferase production was reversed with the co-transfected anti-miR in 
culture (Fig. 17A). Similar results were also obtained for miR-204 with both CD44 and 
BHLHE41 (31.4% and 29.9% decreases respectively) (Fig. 17C) as well as miR-211 
and DUSP6 (12.1% decrease in expression) (Fig. 17B).   
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A                     B 
  
C 
 
Figure 17 - Luciferase expression of CAD-related miR target genes. The expression of proposed and 
established miR targets decreases by approximately, 14% in  miR-142-3p (A), 12% in miR-211 (B), and 
30% in miR-204 (C). The decreased expression was reversed with co-transfection of the corresponding 
miR inhibitor which is a oligonucleotide sequence that is a perfect complement to the mature miR 
sequence, * = p-value < 0.05. 
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The luciferase assay results confirm our previous results of over-expressing the CAD-
related miRs in HEK293 cell culture; providing evidence of a direct relationship between 
the CAD-related miRs and their proposed targets. The differential expression of the 
CAD-related miRs appears to trigger the gene changes observed in the mRNA 
signature of CAD-IFTA. Factors that trigger the up-regulation of miR-142-3p and 
repression of miRs-204 &-211 indicative of CAD-IFTA may be related to the chronic 
inflammatory state of the kidney observed in both delayed graft function and interstitial 
fibrosis and tubular atrophy (2;5;7;24;64;120). Additionally, TNF-α blockade has been 
linked to decreased miR-142-3p expression in cases of psoriasis (121), and miRs-204 & 
-211 are both associated with the modulations of TGF-β mediated inflammatory 
responses that lead to fibrosis (100;102). Thus testing the effects of inflammatory stimuli 
on miR expression may provide some insight into target interaction and miR expression. 
To test the effect of inflammatory stimuli on the expression of the CAD-related miRs and 
their targets, HEK293 cells were transfected with 500ng of pre-miR sequence plasmid 
from one of the CAD-related miRs and after 24 hours the cells were treated with media 
containing low (5ng/ml) and high (25ng/ml) concentrations of tumor necrosis factor-
alpha (TNF-α), along with untreated vehicle (Veh) controls. Following 8 and 24-hour 
incubations, the cells were collected, their RNA was isolated and assessed for miR and 
mRNA expression using RT-qPCR. Inflammatory stimuli increased over-expression in 
cells that were seeded with pre-miR sequence plasmids prior to the inflammatory 
stimulus (Figs. 18A, 19A, 20A). The effects of inflammatory stimuli on target gene 
expression are not neatly coupled to the observed miR expression.  
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Over expression of miR-142 that was augmented in the inflammatory state (Fig. 18A), a 
concurrent decrease in expression of the established miR-142-3p target, ADCY9, was 
observed after both 8 & 24-hour treatments with TNF-α (Fig. 18B). After the 8-hour 
TNF-α treatment, ADCY9 expression decreased by 22.4% and 23.4% for the low and 
high dose treatments respectively. The 24-hour ADCY9 expression increased at every 
TNF-α dosage compared to the 8-hour time point, but the low dose showed a 13.8% 
decrease compared to the untreated control, while the high dose expression decreased 
by 21.7 percent.  TMEM14A expression is consistently decreased in the presence of 
miR-142-3p over-expression; however, with increasing time and concentration of TNF-α 
treatments the TMEM14A expression increases (Fig. 18B). TMEM14A expression 
remains near 50% of median expression during the 8-hour time point at untreated, low 
dose, and high dose TNF-α treatments. After the 24-hour TNF-α treatment, the 
TMEM14A expression pattern changes, with increases of 14.1% and 30.7% from 
untreated controls at the low and high doses respectively, but TMEM14A expression 
never rises beyond median expression levels.  
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Figure 18 - miR-142-3p and target expression following TNF-α treatment. miR-142-3p expression (A) 
and ADCY9 & TMEM14A expression (B). The  miR expression increased with TNF-α treatments at both 
8hr and 24hr timepoints (A). ADCY9 expression falls with rising inflammatory stimuli during both time 
points. TMEM14A expression remains stably decreased after 8-hour treatment, and increases, but 
remains down-regulated post 24-hour treatment. * = p < 0.05 
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Over-expression of miR-204  increases with TNF-α concentration and at all treatment 
concentrations between the 8-hour and 24-hour timepoints.(Fig. 19A). The inflammatory 
stimulus also decreased expression of the established miR-204 target BCL2L2, in 
addition to the proposed targets, BHLHE41 & CD44 molecule (Fig. 19B). The 
established target, BCL2L2, had a 7.1% decrease in expression from untreated controls 
following an 8-hour treatment with 5ng/ml TNF-α. BCL2L2 expression decreased 25.8% 
from untreated controls following an 8-hour treatment with 25ng/ml TNF-α. The 
decreases in BCL2L2 expression at the 24-hour timepoint were 42.6% and 66.7% for 
the 5ng/ml and 25ng/ml TNF-α treatments respectively. BHLHE41 and CD44 
expression show a similar patterns of expression after 8-hour TNF-α treatments. Both 
BHLHE41 and CD44 expressions increase from control expression after the 5ng/ml 
treatment and decrease 31.2% and 50.5% respectively after 25ng/ml treatment (Fig. 
19B). BHLHE41 expression decreases after the 24-hour TNF-α treatments by 75.7% 
and 61.9% for the 5ng/ml and  25ng/ml treatments respectively. CD44 expression 
decreases 20.6% after the 24-hour 5ng/ml TNF-α treatment, and increases after the 
25ng/ml 24-hour treatment, reversing the pattern seen in the 8-hour time point (Fig. 
19B).  
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Figure 19 - miR-204 and target expression following TNF-α treatment. miR-204 expression is 
increased in response to TNF-α treatments at both 8 & 24 hours (A). Decreases in expression of BCL2L2, 
an established miR-204 target, and the proposed targets, BHLHE41 and CD44, are seen in response to 
TNF-α  treatments, but exhibit different patterns. BCL2L2 falls with increasing TNF-α dosing, while 
BHLHE41 and CD44 expressions spike at the 8-hr low dose (5ng/ml) TNF-α treatment and decreases at 
the 24 hours. High dose (25ng/ml) TNF-α treatment decrease BHLHE41 and CD44 expression short term 
(8hrs) and the expression begins to rebound at 24hrs (B). * = p < 0.05 
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Figure 20 - miR-211 and target expression following TNF-α treatment. MicroRNA-211 overexpression 
increases in response to TNF-α treatments and between the 8-hour and 24-hour time points in the 
untreated controls (A). Expression of the miR-211 target, DUSP6 decreased as TNF-α dosing and 
incubation time increased. After an 8-hour treatment with low and high dose TNF-α, DUSP6 expression 
decreased by 15.3% and 20.8% from untreated control levels respectively (B). After a 24-hour incubation, 
there was a 17% decrease in DUSP6 expression compared to expression levels following the 8-hour 
incubation.  High dose TNF-α treatment resulted in a 12.8% decrease in DUSP6 from untreated controls 
in the 24-hour  TNF-α incubation. These results are in keeping with the established relationship between 
miR-211 and DUSP6. (Fig. 17D). * = p < 0.05 
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Using inflammation to precipitate alterations in miR expression resulted in increased 
expression of miR-142-3p, miR-204, and miR-211 compared to plasmid transfection 
alone. The DNA transfection  weight (500ng) was chosen based on data gathered on 
transfection efficiency (Fig. 14), miR expression (Fig. 15) and target expression (Fig. 
16). The results are in agreement with the relationships between the CAD-related miRs 
and their targets established  by previous data (Fig. 17). The consistency in pattern, and 
degree, of the changes in miR expression with exposure, albeit short-term, to 
inflammatory stimuli, indicate that inflammation alone may not be enough to trigger the 
up-regulation of miR-142-3p and  the concurrent down-regulation of miR-204 and miR-
211 that is consistent with renal CAD-IFTA.  
Conclusions 
 
 
The main goal of this work was to find out if metrics that are otherwise seen as markers 
of disease have some level of functional importance to the development of the diseases 
which they measure. We were able to identify parallels between organ quality, organ 
handling and DGF in our patient cohort and then used tissue array data to identify the 
gene dysregulation and molecular processes that contribute to ischemia reperfusion 
injury and DGF development. There may be an opportunity to create a panel of gene 
markers for DGF, and more interestingly the increased inflammation observed in IRI 
and DGF are linked to molecular processes that can be directly regulated or be 
regulated by miRs including one of our miRs of interest, miR-142-3p (40;86;88;89). 
These findings give some credence to the thought that IRI, DGF, and even CAD-IFTA 
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begin developing in the initial moments post-reperfusion, and that the development of all 
three may be directed by changes in miR expression and activity.  
Because obtaining urine samples from patients with poorly or non-functioning kidneys 
post-operatively is not feasible, follow-up experimentation from otherwise easily 
obtainable urine samples would have to necessarily rely on invasive tissue biopsies or 
less invasive but less informative blood testing to assess miR activity in DGF 
development. As long as the goal remains to assess function based on information from 
non-invasive sources, there will be limitations to the effectiveness of studying IRI and 
DGF in the clinical setting without access to patients’ biopsy tissue.    
The data on miR expression from patient urine samples that we produced showed that 
there was a difference in miR expression of miR-142-3p, miR-204 and miR-211 
between the CAD-IFTA and normal allograft patient groups, which agrees with the 
previous work on the expression of these miRs in CAD-IFTA (38). Our attempt to test 
the consistency of the CAD-IFTA miR-expression pattern, led to the inclusion of patients 
that were not included in our previous work. Specifically, we delineated between those 
patients without pathology, but with poor function (eGFR <60 ml/min/1.73m2); and those 
patients with milder IFTA pathology, but no clinical manifestations of dysfunction (IFTA 
only, Table 10). Including these two extra groups in our analysis, with their 
classifications being based on a single clinical metric, resulted in a more complex 
analysis of our patient cohort. The added layer of complexity, and our reliance on gene 
expression metrics that minimize bias and measure each patient individually, dampened 
the robust fold change differences observed in our previous work, and in the case of 
miR-204 and miR-211 expression, practically eliminated it altogether. Post-hoc testing 
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that compared only patients with CAD-IFTA and those with normal allografts was 
necessary to establish the previously observed patterns of miR expression associated 
with CAD-IFTA.    
The gene expression of the proposed miR targets in the urine samples showed a 
significant increase in CD44 expression in between the patient groups (Fig. 12). These 
results coupled with its anti-correlation tomiR-204 expression, the known roles of CD44 
as key regulator of TGF-β-mediated fibrogenesis & apoptosis (111;112;122), and 
CD44’s role as a regulator of the fibrogenic miR-21 (123-125) (Fig. 21), come together 
to paint a picture where  CD44 is one of the earliest activators of the cell processes 
seen in IRI, DGF, and CAD-IFTA. Furthermore, the loss of miR-204 function in renal 
transplant injury (and perhaps renal injury generally) may be a key regulator in 
development of renal transplant injury and a potential path of exogenous treatment for 
renal transplant injury. These results, and the expressions of the other 3 miR targets, 
should be expanded to a well defined groups of patients with CAD-IFTA and normal 
functioning allografts to validate anti-correlation between the urine sample miR and 
gene target expression in patients with and without CAD-IFTA. 
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Figure 21 - CD44 control of miR-21 expression. From Bourguignon et al. (2012), schematic of 
proposed model of miR-21 expression secondary to CD44 mediated activation of the stem cell marker, 
Nanog, and STAT3 in head and neck squamous cell carcinoma. 
The over-expression of miRs-142-3p, -204, & -211 in HEK293 cells illustrated the ability 
of the cells machinery to process mature, detectable miRs from a pre-miR sequence. 
The titratable effect of miR expression with increasing amounts of seeded DNA (Fig. 
15), implied that target gene expression would also have a similar effect though anti-
correlated to miR expression. The targets for miR-142-3p, TMEM14A, and miR-204, 
CD44 and BHLHE41, all showed decreased expression compared to the cohort median 
(Fig.16 A-C). TMEM14A expression decreased with increasing miR-142-3p expression 
(Fig. 16A), while both the miR-204 targets maintained a less defined pattern of 
decreased expression (Fig. 16B-C). The observed relationship between miR-211 and its 
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proposed target, DUSP6, was a direct correlation, with DUSP6 expression increasing 
with miR-211 concentration, rather than the expected anti-correlation (Fig. 16D). It is 
possible that miR-211 binding DUSP6 is not degrading the mRNA, simulteously 
triggering a positive feedback response and leaving the gene product viable for 
detection upon post-transfection RT-qPCR. Another explanation could be that miR-211 
is driving DUSP6 production. Some miRs have been shown to trigger transcriptional 
and translational activation mechanisms (65;75;77;79;80). There is increasing evidence 
that miRs are also associated with increased translational activity. The difference 
between miR-induced repression and activation has been linked to miR binding to 5’-
untranslated regions of transcripts (82) and more recently to the proliferative state of the 
cell; where miRs repress translation in actively proliferating cells and increase 
translation in quiescent cells (75;79;80). The proposed mechanism of miRNA-induced 
translation activation is not as well elucidated as its inhibitory counterpart, but it may be 
linked to a decrease in GW182 production seen particularly in states of cellular 
quiescence (80;126). Without assaying the cells for metrics of viability, it is difficult to 
say whether the state of the cell affected the miR-target relationship only in the case of 
miR-211 and DUSP6, but it may warrant further study. 
The luciferase assays confirmed the relationships between the CAD-related miRs and 
their proposed targets (Fig. 17). The decrease in luciferase protein gives some insight 
into the miR-target relationship of all 3 CAD-related miRs, including miR-211, which 
appeared to increase DUSP6 expression in miR-211 over-expression assays (Fig. 
16D). The decreased luciferase production in the miR-211-DUSP6 interaction shows 
that miR-211 binds the DUSP6 3’-UTR and inhibits protein production. This outcome, 
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coupled with previous data from miR-211 over-expression, shows that miR-211-DUSP6 
interaction results in an isolated decrease in DUSP6 expression that may trigger 
alternate pathways for DUSP6 expression. 
In summary, this work aimed to take miRs that were thought to be possible biomarkers 
of CAD-IFTA and explore the idea that they may not just be biomarkers, but also be 
mediators of renal transplant dysfunction. By relating the expression of miRs-142-3p, -
204, & -211 to genes that are differentially expressed in CAD-IFTA, we attempted to 
identify potential mechanisms for the miR effect beyond their currently understood 
cellular functions. The increase of miR-142-3p and the loss of miR-204 and miR-211 are 
linked to genes that play roles in promoting apoptosis, inflammation, and fibrosis. 
Further exploration of these miRs within these cellular processes is necessary to 
elucidate a complete functional mechanism, but the results presented here show 
promise that these miRs play a role in renal transplant injury. The ability to assess the 
levels of these 3 miRs in the urine presents a clinical picture of a  panel of disease 
mediators and potential pharmaceutical targets that can also be easier to consistently 
monitor in patients than the current clinical standards of eGFR and tissue biopsies. 
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Appendix A – negatively correlated  targets of miR-142-3p 
MicroRNA Probeset Gene Symbol Pearson Coefficient 
p-
value 
Empirical 
p-value 
hsa-miR-
142-3p 
210397_at DEFB1 -0.977 1.15E-
06 
4.68E-05 
hsa-miR-
142-3p 
218477_at TMEM14A -0.966 5.33E-
06 
4.99E-04 
hsa-miR-
142-3p 
206716_at UMOD -0.965 6.33E-
06 
6.25E-04 
hsa-miR-
142-3p 
221542_s_at ERLIN2 -0.964 7.20E-
06 
7.09E-04 
hsa-miR-
142-3p 
204485_s_at TOM1L1 -0.962 8.69E-
06 
8.34E-04 
hsa-miR-
142-3p 
212448_at NEDD4L -0.956 1.53E-
05 
1.47E-03 
hsa-miR-
142-3p 
205501_at PDE10A -0.956 1.49E-
05 
1.39E-03 
hsa-miR-
142-3p 
213227_at PGRMC2 -0.955 1.68E-
05 
1.60E-03 
hsa-miR-
142-3p 
211941_s_at PEBP1 -0.954 1.88E-
05 
1.72E-03 
hsa-miR-
142-3p 
206414_s_at ASAP2 -0.952 2.25E-
05 
1.87E-03 
hsa-miR-
142-3p 
211033_s_at PEX7 -0.952 2.18E-
05 
1.82E-03 
hsa-miR-
142-3p 
202209_at LSM3 -0.951 2.43E-
05 
2.04E-03 
hsa-miR-
142-3p 
202300_at HBXIP -0.946 3.48E-
05 
2.99E-03 
hsa-miR-
142-3p 
220329_s_at RMND1 -0.946 3.43E-
05 
2.71E-03 
hsa-miR-
142-3p 
219954_s_at GBA3 -0.945 3.72E-
05 
3.08E-03 
hsa-miR-
142-3p 
205761_s_at DUS4L -0.945 3.65E-
05 
3.03E-03 
hsa-miR-
142-3p 
220999_s_at CYFIP2 -0.944 4.06E-
05 
3.25E-03 
hsa-miR-
142-3p 
203067_at PDHX -0.942 4.74E-
05 
3.91E-03 
hsa-miR-
142-3p 
210544_s_at ALDH3A2 -0.942 4.62E-
05 
3.72E-03 
hsa-miR-
142-3p 
220161_s_at EPB41L4B -0.942 4.61E-
05 
3.68E-03 
hsa-miR-
142-3p 
200718_s_at SKP1 -0.941 5.06E-
05 
4.36E-03 
hsa-miR- 206054_at KNG1 -0.941 4.86E- 4.13E-03 
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142-3p 05 
hsa-miR-
142-3p 
207981_s_at ESRRG -0.941 4.83E-
05 
4.04E-03 
hsa-miR-
142-3p 
214598_at CLDN8 -0.94 5.28E-
05 
4.57E-03 
hsa-miR-
142-3p 
211569_s_at HADH -0.94 5.14E-
05 
4.49E-03 
hsa-miR-
142-3p 
221556_at CDC14B -0.939 5.62E-
05 
4.97E-03 
hsa-miR-
142-3p 
202825_at SLC25A4 -0.939 5.53E-
05 
4.89E-03 
hsa-miR-
142-3p 
202000_at NDUFA6 -0.938 6.01E-
05 
5.25E-03 
hsa-miR-
142-3p 
201007_at HADHB -0.937 6.50E-
05 
5.85E-03 
hsa-miR-
142-3p 
213133_s_at GCSH -0.937 6.39E-
05 
5.66E-03 
hsa-miR-
142-3p 
220197_at ATP6V0A4 -0.936 6.93E-
05 
6.17E-03 
hsa-miR-
142-3p 
202960_s_at MUT -0.935 7.22E-
05 
6.44E-03 
hsa-miR-
142-3p 
208732_at RAB2A -0.935 7.22E-
05 
6.40E-03 
hsa-miR-
142-3p 
200972_at TSPAN3 -0.935 7.18E-
05 
6.35E-03 
hsa-miR-
142-3p 
213933_at PTGER3 -0.935 7.10E-
05 
6.31E-03 
hsa-miR-
142-3p 
204556_s_at DZIP1 -0.935 7.04E-
05 
6.22E-03 
hsa-miR-
142-3p 
221620_s_at APOO -0.933 8.22E-
05 
7.38E-03 
hsa-miR-
142-3p 
200659_s_at PHB -0.932 8.79E-
05 
7.52E-03 
hsa-miR-
142-3p 
218024_at BRP44L -0.932 8.40E-
05 
7.43E-03 
hsa-miR-
142-3p 
201121_s_at PGRMC1 -0.931 9.34E-
05 
7.90E-03 
hsa-miR-
142-3p 
201619_at PRDX3 -0.931 9.08E-
05 
7.68E-03 
hsa-miR-
142-3p 
204547_at RAB40B -0.931 9.03E-
05 
7.64E-03 
hsa-miR-
142-3p 
212445_s_at NEDD4L -0.93 9.83E-
05 
8.39E-03 
hsa-miR-
142-3p 
218285_s_at BDH2 -0.93 9.81E-
05 
8.29E-03 
hsa-miR- 202850_at ABCD3 -0.93 9.77E- 8.16E-03 
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142-3p 05 
hsa-miR-
142-3p 
221142_s_at PECR -0.93 9.69E-
05 
8.12E-03 
hsa-miR-
142-3p 
213657_s_at Affy_213657_s_at -0.93 9.51E-
05 
8.03E-03 
hsa-miR-
142-3p 
203608_at ALDH5A1 -0.929 1.04E-
04 
9.27E-03 
hsa-miR-
142-3p 
218789_s_at C11orf71 -0.929 1.02E-
04 
8.86E-03 
hsa-miR-
142-3p 
213346_at C13orf27 -0.929 1.01E-
04 
8.82E-03 
hsa-miR-
142-3p 
203970_s_at PEX3 -0.929 1.01E-
04 
8.78E-03 
hsa-miR-
142-3p 
217963_s_at NGFRAP1 -0.929 1.01E-
04 
8.68E-03 
hsa-miR-
142-3p 
203790_s_at HRSP12 -0.928 1.10E-
04 
9.54E-03 
hsa-miR-
142-3p 
202959_at MUT -0.927 1.11E-
04 
9.63E-03 
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Appendix B – negatively correlated  targets of miR-204 
MicroRNA Probeset Gene Symbol 
Pearson 
Coefficient p-value 
Empirical 
p-value 
hsa-miR-
204 
219694_at FAM105A -0.873 9.64E-
04 
6.53E-04 
hsa-miR-
204 
221565_s_at CALHM2 -0.846 2.02E-
03 
1.44E-03 
hsa-miR-
204 
212796_s_at TBC1D2B -0.842 2.24E-
03 
1.67E-03 
hsa-miR-
204 
219544_at C13orf34 -0.824 3.35E-
03 
2.50E-03 
hsa-miR-
204 
209457_at DUSP5 -0.823 3.44E-
03 
2.63E-03 
hsa-miR-
204 
221530_s_at BHLHE41 -0.823 3.42E-
03 
2.58E-03 
hsa-miR-
204 
203320_at SH2B3 -0.822 3.53E-
03 
2.75E-03 
hsa-miR-
204 
212063_at CD44 -0.821 3.60E-
03 
2.88E-03 
hsa-miR-
204 
218870_at ARHGAP15 -0.817 3.88E-
03 
3.21E-03 
hsa-miR-
204 
44790_s_at C13orf18 -0.815 4.06E-
03 
3.41E-03 
hsa-miR-
204 
220052_s_at TINF2 -0.813 4.28E-
03 
3.67E-03 
hsa-miR-
204 
219471_at C13orf18 -0.812 4.34E-
03 
3.77E-03 
hsa-miR-
204 
204502_at SAMHD1 -0.809 4.58E-
03 
4.18E-03 
hsa-miR-
204 
204563_at SELL -0.803 5.18E-
03 
4.94E-03 
hsa-miR-
204 
212646_at RFTN1 -0.803 5.13E-
03 
4.86E-03 
hsa-miR-
204 
202664_at WIPF1 -0.802 5.29E-
03 
5.11E-03 
hsa-miR-
204 
203086_at KIF2A -0.801 5.39E-
03 
5.25E-03 
hsa-miR-
204 
209360_s_at RUNX1 -0.801 5.38E-
03 
5.20E-03 
hsa-miR-
204 
209683_at FAM49A -0.798 5.62E-
03 
5.80E-03 
hsa-miR-
204 
213113_s_at SLC43A3 -0.797 5.81E-
03 
6.19E-03 
hsa-miR-
204 
203385_at DGKA -0.796 5.87E-
03 
6.23E-03 
hsa-miR- 213241_at PLXNC1 -0.794 6.09E- 6.75E-03 
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204 03 
hsa-miR-
204 
205624_at CPA3 -0.794 6.08E-
03 
6.71E-03 
hsa-miR-
204 
208891_at DUSP6 -0.793 6.25E-
03 
6.88E-03 
hsa-miR-
204 
204780_s_at FAS -0.793 6.20E-
03 
6.80E-03 
hsa-miR-
204 
212959_s_at GNPTAB -0.792 6.29E-
03 
7.02E-03 
hsa-miR-
204 
203409_at DDB2 -0.791 6.48E-
03 
7.29E-03 
hsa-miR-
204 
219014_at PLAC8 -0.791 6.44E-
03 
7.15E-03 
hsa-miR-
204 
204959_at MNDA -0.79 6.59E-
03 
7.65E-03 
hsa-miR-
204 
202663_at WIPF1 -0.789 6.70E-
03 
8.01E-03 
hsa-miR-
204 
210073_at ST8SIA1 -0.787 6.96E-
03 
8.51E-03 
hsa-miR-
204 
210176_at TLR1 -0.787 6.93E-
03 
8.38E-03 
hsa-miR-
204 
202241_at TRIB1 -0.787 6.90E-
03 
8.29E-03 
hsa-miR-
204 
202693_s_at STK17A -0.786 7.05E-
03 
8.55E-03 
hsa-miR-
204 
207075_at NLRP3 -0.778 7.98E-
03 
9.98E-03 
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Appendix C – negatively correlated  targets of miR-211 
MicroRNA Probeset Gene 
Symbol 
Pearson 
Coefficient 
p-value Empirical 
p-value 
hsa-miR-
211 
219544_at C13orf34 -0.831 2.92E-03 1.65E-03 
hsa-miR-
211 
208891_at DUSP6 -0.814 4.15E-03 2.85E-03 
hsa-miR-
211 
203086_at KIF2A -0.79 6.54E-03 5.84E-03 
hsa-miR-
211 
203385_at DGKA -0.786 7.06E-03 6.78E-03 
hsa-miR-
211 
202241_at TRIB1 -0.783 7.45E-03 7.42E-03 
hsa-miR-
211 
213101_s_at ACTR3 -0.767 9.68E-03 1.10E-02 
hsa-miR-
211 
208736_at ARPC3 -0.762 1.04E-02 1.24E-02 
hsa-miR-
211 
219694_at FAM105A -0.757 1.13E-02 1.36E-02 
hsa-miR-
211 
201603_at PPP1R12A -0.751 1.22E-02 1.50E-02 
hsa-miR-
211 
208644_at PARP1 -0.751 1.24E-02 1.54E-02 
hsa-miR-
211 
204527_at MYO5A -0.746 1.32E-02 1.65E-02 
hsa-miR-
211 
218319_at PELI1 -0.744 1.36E-02 1.70E-02 
hsa-miR-
211 
221565_s_at CALHM2 -0.741 1.42E-02 1.80E-02 
hsa-miR-
211 
205126_at VRK2 -0.739 1.45E-02 1.88E-02 
hsa-miR-
211 
213168_at SP3 -0.739 1.47E-02 1.92E-02 
hsa-miR-
211 
209457_at DUSP5 -0.737 1.50E-02 1.96E-02 
hsa-miR-
211 
208296_x_at TNFAIP8 -0.736 1.52E-02 1.98E-02 
hsa-miR-
211 
200791_s_at IQGAP1 -0.734 1.57E-02 2.05E-02 
hsa-miR-
211 
204780_s_at FAS -0.732 1.60E-02 2.12E-02 
hsa-miR-
211 
203696_s_at RFC2 -0.732 1.61E-02 2.14E-02 
hsa-miR-
211 
220052_s_at TINF2 -0.73 1.65E-02 2.20E-02 
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hsa-miR-
211 
203518_at LYST -0.73 1.66E-02 2.23E-02 
hsa-miR-
211 
210176_at TLR1 -0.728 1.69E-02 2.27E-02 
hsa-miR-
211 
204781_s_at FAS -0.728 1.70E-02 2.29E-02 
hsa-miR-
211 
202664_at WIPF1 -0.725 1.78E-02 2.41E-02 
hsa-miR-
211 
219402_s_at DERL1 -0.723 1.81E-02 2.46E-02 
hsa-miR-
211 
203269_at NSMAF -0.723 1.82E-02 2.50E-02 
hsa-miR-
211 
202693_s_at STK17A -0.719 1.91E-02 2.73E-02 
hsa-miR-
211 
213102_at ACTR3 -0.718 1.93E-02 2.77E-02 
hsa-miR-
211 
206991_s_at CCR5 -0.713 2.06E-02 3.04E-02 
hsa-miR-
211 
217947_at CMTM6 -0.708 2.19E-02 3.28E-02 
hsa-miR-
211 
202663_at WIPF1 -0.7 2.42E-02 3.64E-02 
hsa-miR-
211 
210260_s_at TNFAIP8 -0.699 2.46E-02 3.71E-02 
hsa-miR-
211 
218854_at DSE -0.698 2.47E-02 3.72E-02 
hsa-miR-
211 
203320_at SH2B3 -0.697 2.50E-02 3.79E-02 
hsa-miR-
211 
213241_at PLXNC1 -0.696 2.54E-02 3.85E-02 
hsa-miR-
211 
220266_s_at KLF4 -0.692 2.66E-02 4.07E-02 
hsa-miR-
211 
205249_at EGR2 -0.691 2.70E-02 4.14E-02 
hsa-miR-
211 
202672_s_at ATF3 -0.689 2.74E-02 4.22E-02 
hsa-miR-
211 
210073_at ST8SIA1 -0.688 2.78E-02 4.31E-02 
hsa-miR-
211 
204563_at SELL -0.686 2.86E-02 4.44E-02 
hsa-miR-
211 
212377_s_at NOTCH2 -0.685 2.88E-02 4.49E-02 
hsa-miR-
211 
212577_at SMCHD1 -0.684 2.91E-02 4.57E-02 
hsa-miR-
211 
205624_at CPA3 -0.681 3.02E-02 4.82E-02 
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hsa-miR-
211 
201044_x_at DUSP1 -0.68 3.03E-02 4.83E-02 
hsa-miR-
211 
212796_s_at TBC1D2B -0.68 3.04E-02 4.86E-02 
hsa-miR-
211 
201368_at ZFP36L2 -0.68 3.06E-02 4.88E-02 
hsa-miR-
211 
208892_s_at DUSP6 -0.679 3.07E-02 4.92E-02 
hsa-miR-
211 
209189_at FOS -0.679 3.08E-02 4.93E-02 
hsa-miR-
211 
203414_at MMD -0.679 3.10E-02 4.96E-02 
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Appendix D – Differentially Expressed Genes in Reperfusion (K1 vs. K2) in DGF 
146 
Probe 
sets 
only in 
"DGF" 
Gene symbol 
K1           
Mean 
(Log2
) 
K2 
 
Mean 
(Log2
) 
Fold 
Change 
(Geometric
) 
p-
value 
q-
value 
202464_
s_at PFKFB3 8.84 9.98 2.21 
4.04E
-04 
1.83E
-02 
220330_
s_at SAMSN1 6.58 7.45 1.83 
1.06E
-03 
3.27E
-02 
210002_
at GATA6 6.60 7.46 1.81 
1.47E
-03 
3.84E
-02 
201417_
at SOX4 9.03 9.73 1.63 
8.92E
-04 
3.02E
-02 
202779_
s_at LOC731049 /// UBE2S 6.34 6.98 1.56 
1.33E
-03 
3.63E
-02 
203471_
s_at PLEK 6.31 6.90 1.50 
1.11E
-03 
3.32E
-02 
203835_
at LRRC32 8.56 9.08 1.44 
8.22E
-04 
2.90E
-02 
221045_
s_at PER3 6.44 6.94 1.41 
8.90E
-04 
3.02E
-02 
205463_
s_at PDGFA 6.90 7.37 1.38 
2.19E
-03 
4.83E
-02 
214721_
x_at CDC42EP4 7.32 7.79 1.38 
3.06E
-04 
1.50E
-02 
203044_
at CHSY1 8.63 9.09 1.37 
6.79E
-04 
2.59E
-02 
213716_
s_at SECTM1 8.00 8.39 1.31 
2.17E
-03 
4.82E
-02 
203634_
s_at CPT1A 4.86 5.24 1.30 
1.57E
-03 
3.97E
-02 
206472_
s_at TLE3 5.23 5.60 1.29 
2.27E
-03 
4.95E
-02 
220027_
s_at RASIP1 6.92 7.28 1.29 
1.06E
-03 
3.27E
-02 
201313_
at ENO2 5.17 5.53 1.28 
7.15E
-04 
2.65E
-02 
210008_
s_at MRPS12 6.40 6.74 1.27 
1.88E
-03 
4.41E
-02 
209652_
s_at PGF 5.48 5.83 1.27 
1.23E
-04 
8.00E
-03 
211289_
x_at CDC2L1 /// CDC2L2 6.38 6.72 1.26 
1.64E
-03 
4.09E
-02 
218612_
s_at TSSC4 6.56 6.89 1.26 
8.31E
-04 
2.91E
-02 
220510_
at RHBG 7.00 7.32 1.25 
1.60E
-03 
4.02E
-02 
213098_
at RQCD1 6.05 6.36 1.24 
3.78E
-04 
1.75E
-02 
221922_
at GPSM2 5.08 5.38 1.23 
9.60E
-04 
3.13E
-02 
219480_
at SNAI1 5.95 6.25 1.23 
2.14E
-04 
1.18E
-02 
209999_
x_at SOCS1 5.40 5.69 1.23 
1.41E
-03 
3.74E
-02 
214742_ AZI1 5.97 6.27 1.23 1.75E 4.22E
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at -03 -02 
215454_
x_at SFTPC 6.19 6.49 1.22 
2.18E
-03 
4.83E
-02 
211180_
x_at RUNX1 4.94 5.23 1.22 
2.89E
-05 
2.94E
-03 
215280_
s_at PPFIA3 5.62 5.90 1.22 
6.02E
-04 
2.35E
-02 
219798_
s_at MEPCE 8.52 8.80 1.21 
7.05E
-04 
2.63E
-02 
209359_
x_at RUNX1 4.83 5.10 1.21 
1.21E
-03 
3.51E
-02 
210336_
x_at MZF1 7.39 7.66 1.21 
3.05E
-04 
1.50E
-02 
212707_
s_at FLJ21767 /// RASA4 6.29 6.55 1.20 
2.06E
-03 
4.67E
-02 
219609_
at WDR25 6.23 6.48 1.19 
1.55E
-03 
3.96E
-02 
40446_a
t PHF1 9.35 9.60 1.19 
3.71E
-04 
1.73E
-02 
207876_
s_at FLNC 6.24 6.49 1.19 
1.60E
-03 
4.02E
-02 
206827_
s_at TRPV6 6.84 7.09 1.19 
1.29E
-03 
3.60E
-02 
205223_
at DEPDC5 6.15 6.38 1.17 
1.84E
-03 
4.36E
-02 
214133_
at MUC6 6.17 6.40 1.17 
1.77E
-03 
4.26E
-02 
219518_
s_at ELL3 5.67 5.89 1.17 
1.07E
-03 
3.27E
-02 
214148_
at 0 6.48 6.70 1.17 
1.15E
-03 
3.39E
-02 
212048_
s_at YARS 8.46 8.68 1.16 
1.07E
-03 
3.27E
-02 
212356_
at KIAA0323 7.48 7.69 1.15 
1.06E
-03 
3.27E
-02 
210873_
x_at APOBEC3A 4.47 4.67 1.15 
3.66E
-04 
1.71E
-02 
221994_
at PDLIM5 4.62 4.82 1.15 
9.30E
-04 
3.09E
-02 
204014_
at DUSP4 4.38 4.57 1.14 
1.73E
-03 
4.18E
-02 
210726_
at CYP3A4 5.46 5.64 1.14 
1.09E
-03 
3.29E
-02 
217664_
at 0 4.35 4.52 1.13 
1.19E
-04 
7.82E
-03 
214412_
at H2AFB1 /// H2AFB3 6.03 6.19 1.12 
1.03E
-03 
3.24E
-02 
212860_
at ZDHHC18 7.03 7.19 1.12 
9.83E
-04 
3.16E
-02 
210567_
s_at SKP2 4.26 4.39 1.10 
5.05E
-04 
2.08E
-02 
215671_
at PDE4B 3.84 3.96 1.09 
9.63E
-04 
3.13E
-02 
218691_
s_at PDLIM4 4.30 4.40 1.07 
1.66E
-04 
1.01E
-02 
210599_
at ZNF614 5.00 5.09 1.06 
2.11E
-03 
4.73E
-02 
215803_
at CXorf57 3.84 3.92 1.06 
1.71E
-03 
4.18E
-02 
208955_
at DUT 6.71 6.56 -1.11 
9.35E
-04 
3.09E
-02 
207409_ LECT2 4.38 4.23 -1.11 7.67E 2.78E
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at -04 -02 
216387_
x_at LOC390411 9.15 8.99 -1.12 
1.76E
-03 
4.24E
-02 
217340_
at LOC645452 4.72 4.54 -1.13 
1.32E
-05 
1.61E
-03 
201507_
at PFDN1 9.14 8.97 -1.13 
1.49E
-03 
3.87E
-02 
206037_
at CCBL1 7.27 7.09 -1.13 
1.92E
-03 
4.47E
-02 
210525_
x_at C14orf143 4.38 4.20 -1.13 
7.44E
-04 
2.72E
-02 
211628_
x_at FTHP1 13.49 13.31 -1.13 
1.29E
-03 
3.60E
-02 
203609_
s_at ALDH5A1 5.66 5.47 -1.14 
3.95E
-04 
1.81E
-02 
208364_
at INPP4A 5.28 5.09 -1.14 
1.52E
-03 
3.91E
-02 
209517_
s_at ASH2L 9.24 9.05 -1.14 
1.88E
-04 
1.08E
-02 
216532_
x_at LOC728344 8.11 7.92 -1.14 
1.55E
-03 
3.96E
-02 
218534_
s_at AGGF1 8.67 8.47 -1.15 
1.97E
-03 
4.54E
-02 
219217_
at NARS2 8.43 8.22 -1.16 
5.57E
-04 
2.24E
-02 
211955_
at RANBP5 8.96 8.75 -1.16 
1.29E
-03 
3.60E
-02 
216315_
x_at Kua-UEV /// LOC730052 /// UBE2V1 5.39 5.18 -1.16 
1.48E
-03 
3.85E
-02 
220149_
at C2orf54 6.48 6.26 -1.16 
1.59E
-03 
4.01E
-02 
203630_
s_at COG5 7.89 7.67 -1.17 
8.27E
-04 
2.90E
-02 
206369_
s_at PIK3CG 4.90 4.66 -1.18 
8.69E
-04 
2.98E
-02 
217249_
x_at 0 11.19 10.94 -1.18 
4.06E
-06 
6.95E
-04 
214647_
s_at HFE 5.11 4.87 -1.18 
1.00E
-03 
3.20E
-02 
218185_
s_at ARMC1 9.50 9.26 -1.19 
2.09E
-03 
4.71E
-02 
219385_
at SLAMF8 6.23 5.98 -1.19 
7.38E
-04 
2.72E
-02 
202349_
at TOR1A 7.99 7.73 -1.20 
1.71E
-03 
4.18E
-02 
216383_
at 
hCG_2040224 /// LOC285053 /// 
LOC390354 /// LOC729955 /// RPL18A 8.04 7.78 -1.20 
1.28E
-03 
3.60E
-02 
211557_
x_at SLCO2B1 6.80 6.53 -1.21 
2.23E
-03 
4.89E
-02 
203505_
at ABCA1 9.64 9.36 -1.21 
1.34E
-03 
3.63E
-02 
203843_
at RPS6KA3 8.14 7.86 -1.21 
1.87E
-03 
4.41E
-02 
201838_
s_at SUPT7L 6.87 6.59 -1.22 
3.05E
-04 
1.50E
-02 
205402_
x_at PRSS2 5.37 5.08 -1.22 
3.63E
-04 
1.70E
-02 
211014_
s_at LOC161527 /// LOC652671 /// PML 6.37 6.09 -1.22 
1.53E
-03 
3.92E
-02 
207821_
s_at PTK2 8.64 8.35 -1.22 
2.20E
-03 
4.85E
-02 
201856_ ZFR 7.60 7.31 -1.22 1.12E 3.34E
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s_at -03 -02 
200890_
s_at SSR1 8.72 8.43 -1.22 
1.03E
-03 
3.24E
-02 
217135_
x_at 0 7.28 6.99 -1.22 
1.72E
-04 
1.02E
-02 
219671_
at HPCAL4 6.03 5.73 -1.22 
1.88E
-03 
4.41E
-02 
204074_
s_at KIAA0562 7.24 6.95 -1.23 
2.06E
-03 
4.67E
-02 
217939_
s_at AFTPH 10.40 10.10 -1.23 
7.23E
-04 
2.67E
-02 
209476_
at TXNDC1 10.61 10.31 -1.24 
1.60E
-03 
4.02E
-02 
208848_
at ADH5 10.16 9.86 -1.24 
1.73E
-03 
4.18E
-02 
211460_
at TTTY9A /// TTTY9B 5.26 4.95 -1.24 
4.42E
-04 
1.94E
-02 
202132_
at WWTR1 8.23 7.92 -1.24 
1.51E
-03 
3.90E
-02 
220007_
at METTL8 6.60 6.29 -1.24 
4.58E
-04 
1.98E
-02 
211994_
at WNK1 10.48 10.16 -1.25 
7.54E
-04 
2.75E
-02 
202100_
at RALB 10.35 10.03 -1.25 
1.47E
-03 
3.84E
-02 
206770_
s_at SLC35A3 9.43 9.10 -1.25 
1.69E
-03 
4.15E
-02 
201943_
s_at CPD 8.16 7.83 -1.25 
1.03E
-03 
3.24E
-02 
203359_
s_at MYCBP 8.80 8.46 -1.26 
6.94E
-04 
2.62E
-02 
205942_
s_at ACSM3 8.33 7.98 -1.27 
1.84E
-03 
4.36E
-02 
214224_
s_at PIN4 10.11 9.76 -1.27 
2.10E
-03 
4.72E
-02 
219287_
at KCNMB4 7.31 6.96 -1.28 
9.29E
-04 
3.09E
-02 
209484_
s_at NSL1 9.45 9.09 -1.28 
1.17E
-03 
3.43E
-02 
201067_
at PSMC2 9.40 9.05 -1.28 
1.19E
-04 
7.82E
-03 
202053_
s_at ALDH3A2 10.65 10.29 -1.28 
1.15E
-04 
7.73E
-03 
210154_
at ME2 6.57 6.20 -1.29 
1.42E
-03 
3.75E
-02 
211960_
s_at RAB7A 9.83 9.45 -1.29 
1.42E
-03 
3.75E
-02 
203243_
s_at PDLIM5 9.60 9.22 -1.31 
1.68E
-03 
4.13E
-02 
214724_
at DIXDC1 8.71 8.31 -1.32 
9.34E
-04 
3.09E
-02 
210840_
s_at IQGAP1 8.52 8.12 -1.32 
9.73E
-04 
3.14E
-02 
209404_
s_at TMED7 10.02 9.62 -1.32 
1.85E
-03 
4.38E
-02 
200745_
s_at GNB1 10.11 9.70 -1.32 
1.14E
-03 
3.37E
-02 
219558_
at ATP13A3 7.18 6.78 -1.32 
1.46E
-03 
3.83E
-02 
201198_
s_at PSMD1 9.06 8.65 -1.33 
1.65E
-03 
4.11E
-02 
202378_ LEPROT 11.53 11.12 -1.33 2.15E 4.80E
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s_at -03 -02 
221745_
at WDR68 7.62 7.20 -1.34 
8.17E
-04 
2.90E
-02 
216650_
at LOC650303 /// LOC729105 7.18 6.75 -1.35 
2.77E
-04 
1.41E
-02 
202592_
at BLOC1S1 9.64 9.20 -1.36 
1.25E
-03 
3.56E
-02 
200760_
s_at ARL6IP5 10.05 9.61 -1.36 
1.45E
-04 
9.10E
-03 
201732_
s_at CLCN3 7.50 7.04 -1.37 
1.32E
-03 
3.62E
-02 
212582_
at OSBPL8 10.77 10.32 -1.37 
7.00E
-04 
2.62E
-02 
205606_
at LRP6 7.88 7.43 -1.37 
1.17E
-03 
3.42E
-02 
36920_a
t MTM1 7.47 7.02 -1.37 
1.25E
-03 
3.56E
-02 
217832_
at SYNCRIP 8.91 8.45 -1.37 
1.71E
-03 
4.18E
-02 
216348_
at LOC402057 /// RPS17 9.72 9.26 -1.37 
8.77E
-04 
2.99E
-02 
205371_
s_at DBT 7.68 7.20 -1.39 
9.22E
-04 
3.09E
-02 
200729_
s_at ACTR2 9.85 9.36 -1.41 
8.59E
-04 
2.97E
-02 
212634_
at KIAA0776 8.10 7.61 -1.41 
1.24E
-03 
3.56E
-02 
216521_
s_at BRCC3 5.85 5.34 -1.42 
1.61E
-03 
4.02E
-02 
205882_
x_at ADD3 10.48 9.97 -1.42 
1.91E
-03 
4.46E
-02 
205369_
x_at DBT 7.16 6.63 -1.45 
2.56E
-04 
1.34E
-02 
220038_
at SGK3 7.88 7.34 -1.45 
5.40E
-04 
2.19E
-02 
218967_
s_at PTER 10.32 9.77 -1.47 
7.07E
-04 
2.63E
-02 
201411_
s_at PLEKHB2 9.91 9.34 -1.49 
1.42E
-03 
3.75E
-02 
201646_
at SCARB2 8.69 8.10 -1.51 
1.30E
-03 
3.62E
-02 
220342_
x_at EDEM3 6.69 6.08 -1.52 
1.18E
-03 
3.44E
-02 
221041_
s_at SLC17A5 8.61 8.00 -1.53 
1.87E
-04 
1.08E
-02 
211992_
at WNK1 9.99 9.37 -1.53 
1.06E
-03 
3.27E
-02 
219948_
x_at UGT2A3 11.48 10.74 -1.66 
1.05E
-03 
3.27E
-02 
218700_
s_at RAB7L1 9.49 8.73 -1.70 
2.68E
-04 
1.38E
-02 
213362_
at PTPRD 8.00 7.19 -1.76 
8.20E
-04 
2.90E
-02 
201971_
s_at ATP6V1A 9.09 8.17 -1.89 
5.51E
-04 
2.23E
-02 
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